



**HAL**  
open science

# Dietary modulation of large extracellular vesicles: the good and the bad for human health

Laurent-Emmanuel Monfoulet, M. Carmen Martínez

► **To cite this version:**

Laurent-Emmanuel Monfoulet, M. Carmen Martínez. Dietary modulation of large extracellular vesicles: the good and the bad for human health. *Nutrition Reviews*, 2022, 80 (5), pp.1274-1293. 10.1093/nutrit/nuab106 . hal-03531018

**HAL Id: hal-03531018**

**<https://hal.science/hal-03531018v1>**

Submitted on 31 Mar 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

1 **Special Article**

2

3 **Dietary modulation of large extracellular vesicles: the good and the bad for human health**

4

5 Laurent-Emmanuel Monfoulet<sup>1,✉</sup> and Maria Carmen Martinez<sup>2</sup>

6 <sup>1</sup> Université Clermont Auvergne, INRAE, UNH, F-63000 Clermont-Ferrand, France

7 <sup>2</sup> SOPAM, U1063, INSERM, UNIV Angers, SFR, ICAT, Angers, France

8

9 **Corresponding author:**

10 Laurent-Emmanuel Monfoulet

11 laurent-emmanuel.monfoulet@inrae.fr

12 INRAE, Centre de Recherche Clermont Auvergne – Rhône-Alpes, Human Nutrition Unit (UNH), 63122 Saint

13 Genès Champanelle, France

14

15 **Abstract**

16 Extracellular vesicles encompassing nanovesicles derived from the endosome system and generated by  
17 plasmatic membrane shedding, become of increasing interest in view of their ability to sustain a cell-to-  
18 cell communication and with the possibility to be used as surrogate biomarkers of healthy and unhealthy  
19 trajectories. Over the last decades, nutritional strategies have been developed to preserve health and  
20 their impact on circulating EVs is arousing a growing interest. Data available from published studies are  
21 now sufficient for a first integration in order to better understand the role of EVs in the relation between  
22 diet and health. Thus, this review focuses on human intervention studies investigating the impact of diet  
23 or its components on circulating EVs. Due to analytical bias, only large EVs have been assessed so far. The  
24 analysis highlights that poor-quality diets with elevated fat and sugar content increase levels of circulating  
25 large EVs that can be partly counteracted by healthy food or some food micronutrients and bioactive  
26 compounds. However, knowledge on the content and the biological functions of these diet-induced EVs  
27 are still missing. It is of crucial importance to address these aspects in new research in order to state on  
28 EVs as mediators of the effects of diet on health.

29

30 **Keywords**

31 Extracellular vesicles, microparticles, exosomes, diet, dietary constituents, human intervention studies,  
32 risk factor, nutritional biomarkers

33

34 **Introduction**

35 Dietary pattern is an important driver of non-communicable diseases (NCDs) such as obesity,  
36 diabetes and metabolic syndrome leading to cardiovascular diseases (CVD). In western societies,  
37 individuals are routinely exposed to postprandial lipaemia, hypertriglyceridaemia and hyperglycaemia  
38 that have been shown to be risk factors for CVD<sup>1,2</sup> including coronary artery diseases (CAD)<sup>3,4</sup>, and that  
39 contribute to the development of atherosclerosis<sup>5,6</sup>. These metabolic changes induce particularly the  
40 activation of circulating immune cells and endothelial cells, one feature of which is the increased release

41 of circulating extracellular vesicles (EVs) <sup>7, 8</sup>. EVs, including small EVs (previously called exosomes ; S-EVs)  
42 and large EVs (known as microparticles; L-EVs), are shed membrane particles of less than 1µm in diameter  
43 that emerged as candidate meaningful biomarker for the diagnosis and the prognosis of cardiometabolic  
44 disorders <sup>9-14</sup>. S-EVs are vesicles of endo-lysosomal origin that are released as a consequence of the fusion  
45 of the multivesicular endosome (namely MVB) with the plasma membrane, whereas L-EVs are generated  
46 by budding and fission of the plasma membrane <sup>8</sup>. Both EV subtypes convey proteins, nucleic acids and  
47 lipids with the possibility to be used as markers and conferring to EVs the ability to sustain a cell-to-cell  
48 communication. As an example, circulating endothelial L-EVs and their increased level in plasma assessed  
49 at fasting state are both emerging biomarkers and active effectors of endothelial dysfunction in CVD <sup>15-17</sup>.  
50 Similarly, Crewe et al. <sup>18</sup> demonstrated that S-EVs are produced locally by endothelial cells in the adipose  
51 tissue in fasting mice, but not after feeding. In addition to demonstrate that EVs are regulated by  
52 fasting/refeeding, the authors suggest that EVs participate the tissue response to metabolic changes in  
53 the systemic nutrient state.

54 Since the 2000s, the relationship between diet and circulating EVs has been the subject of  
55 numerous studies. Dietary interventions in animal models have demonstrated that chronic high-energy  
56 diet (e.g. high fat or high carbohydrate diet) results in an increased level of circulating S-<sup>19</sup> and L-EVs <sup>20-22</sup>.  
57 Inversely, plant-based diets are highly protective for health <sup>23</sup>. This is partly attributed to EV-associated  
58 plant bioactive compounds, especially polyphenols with a body of evidence in preventing cardiometabolic  
59 diseases especially through the reduction of vascular dysfunctions associated with ageing and unbalanced  
60 nutrition <sup>24-26</sup>. In addition to improve endothelial function, diet supplemented with polyphenols from red  
61 wine has been shown to lower the level of endothelial EVs circulating at fasting state in a rodent model of  
62 hypertension <sup>27</sup>.

63 Interestingly, food such as fruits and vegetables and cow milk-based products <sup>28, 29</sup> are dietary  
64 sources of exogeneous EVs (mainly S-EVs) namely EV-like nanoparticles. As other EVs, they convey  
65 proteins, lipids and nucleic acids in a phospholipid bilayer, but they can also encompass nutrients and/or  
66 plant bioactive compounds such as polyphenols <sup>30, 31</sup>. These S-EVs have been demonstrated to be

67 absorbed, detected in host tissues few hours after their intake. The biological effects of EV-like  
68 nanoparticles on the physiology of the consumer is a matter of concern.

69         The close relationship between diet and health, and the growing development of EV-based  
70 biomarkers in medicine make necessary to consider the modulation of EVs by the diet, both at fasting and  
71 postprandial states in humans. The present review focuses on human interventions investigating the  
72 impact of a single meal and of a chronic intake on circulating EVs. It also introduces how dietary  
73 compounds act to trigger physiological pathways controlling the biogenesis and/or the release of  
74 endogenous EVs. Finally, this review provides reports on the biological functions of diet-associated EVs  
75 and raises the need for further investigations in this domain, especially in order to provide an accurate  
76 phenotyping of diet-induced EVs.

77

#### 78         **1. Why human nutritional intervention studies focused on L-EVs?**

79         Since the 2000s, 29 interventional studies have investigated the impact of diet and their constituents  
80 on circulating EVs in Humans. In these nutritional intervention studies, EVs were analysed on platelet-  
81 poor or platelet-free plasma (PPP or PFP) obtained by centrifugation of blood samples up to 17,000 *g*. This  
82 centrifugation pellets platelets but not the L-EVs and S-EVs that need longer centrifugation at 20,000 *g* or  
83 100,000 *g* to be pelleted respectively<sup>32</sup>. In these PPP/PFP, EVs were detected by flow cytometry based on  
84 different combinations of constitutive and/or inducible surface markers (Table 1) after immunostaining.  
85 This strategy of analysis limits the detection and the quantification to specific EV subtypes. First, the  
86 conventional flow cytometers used in these studies (LSRII, FACSAria, FACScan, Canto, FC500, FACSCalibur)  
87 are not sensitive enough to do detect scattered light or emitted fluorescence from particles smaller than  
88 300 nm in diameter, and therefore do not allow the direct detection of S-EVs<sup>33, 34</sup>. In addition, plasma  
89 lipids (e.g. chylomicrons) due to their size may interfere with the detection of EVs by flow cytometry<sup>35</sup>. To  
90 avoid this limit, a fluorescent staining mainly based on the detection of phosphatidylserine specifically  
91 expressed at the surface of L-EVs was used. Therefore, this explains why these nutritional intervention  
92 studies only report on the effect on L-EVs.

93 Above methodological aspects, the interest in L-EVs may be explained by a greater susceptibility of L-  
94 EVs to changes in response to a stimulus than S-EVs<sup>36, 37</sup>. Moreover, the content in proteins of L-EVs was  
95 reported as closer to those of the donor cell than the proteome of S-EVs<sup>36, 38</sup>, thus strengthening the  
96 interest for the L- EVs in human intervention studies. However, it is worth noting that the secretion, the  
97 content and the bioactivity of S-EVs have been reported in *in vitro* studies as modulated by nutritional  
98 factors such as hyperglycaemia<sup>39-41</sup> or polyphenol supplementations<sup>42-44</sup>.

99 Among the subpopulations of EVs present in plasma, endothelial L-EVs whose proportion is estimated  
100 to less than 5% are the most investigated ahead of platelet- and erythrocyte-derived L-EVs which account  
101 for 70%-95% and 8-16% of the total plasma L-EVs, respectively<sup>45-49</sup>. This large interest in endothelial L-EVs  
102 can be explained by the widely documented contribution of endothelial dysfunction in the development  
103 and the complications of cardiometabolic diseases<sup>50</sup>. Whatever the subtype of EVs investigated, human  
104 intervention studies were controlled by ethical considerations that limit the number and volume of blood  
105 sampling and therefore that constrain studies to few timepoints after a nutritional intervention. By  
106 consequence, knowledge on the pharmacokinetic of EVs during the postprandial period is still incomplete.  
107 Cross-over and/or a placebo control designs have been used to ascertain the impact of dietary intakes on  
108 circulating L-EVs. They allowed to demonstrate first the variation of the circulating L-EVs during the  
109 postprandial period induced by an acute diet intake (Table 2) and secondarily the effect of chronic intakes  
110 on the basal circulating L-EVs at fasting (Table 3).

111

Cell source of large EVs (namely microparticles)	Cluster of differentiation staining	Protein Symbol	Full name
Endothelial MPs	CD31+ CD41- CD42a- CD42b- CD45- CD62b- CD62e+ CD105+ CD106 CD144+ CD146+	PECAM1 ITGA2B GP9 Gplb PTPRC SELP SELE ENG VCAM1 CDH5 MCAM	platelet and endothelial cell adhesion molecule 1 integrin subunit alpha 2b glycoprotein IX platelet glycoprotein Ib platelet protein tyrosine phosphatase receptor type C selectin P selectin E endoglin vascular cell adhesion molecule 1 cadherin 5 melanoma cell adhesion molecule
Platelet MPs	CD41+ CD42b+ CD61+ CD62b+ Fibrogen+ TF(CD142)+	ITGA2B Gplb ITGB3 SELP FGB F3	integrin subunit alpha 2b glycoprotein Ib platelet integrin subunit beta 3 selectin P fibrinogen beta chain coagulation factor III, tissue facto
Leukocyte MPs	CD4+ CD8 CD11a+ CD11b+ CD41- CD45+	CD4 CD8A ITGAL ITGAM ITGA2B PTPRC	CD4 molecule CD8a molecule integrin subunit alpha L integrin subunit alpha M integrin subunit alpha 2b protein tyrosine phosphatase receptor type C

**Table 1: Cell surface markers used for the identification of EV subpopulations by flow cytometry.**

112

113

114 **Table 2: Clinical trials investigating the impact of acute dietary intakes on EVs during the postprandial period.**

Publication	Study design	Country	Participants	Intervention	Investigated EVs	Main results
Bulut et al. J Cardiovasc Pharmacol 2013 51	Randomized Cross-over	EU (Germany)	Healthy men (n= 10) Age= 44.2 ± 9.6 BMI= 24.4 ± 2.5	A single meal of French fries and hot pork sausage with sauce (1,200 kcal: 50 % from Fat; 30 % CHO; 20 % Proteins) ± 200 mL water or 200 mL coca cola or 100 mL red wine/10 OmL water, or 36 mL liquor (38 vol %)/164 mL water	AnnexinV <sup>+</sup> L-EVs: ▪ CD31 <sup>+</sup> /CD42b <sup>-</sup> endothelial L-EVs ▪ CD31 <sup>+</sup> /CD42b <sup>+</sup> platelet L-EVs From platelet-poor plasma By flow cytometry (FACScalibur, BD)	<ul style="list-style-type: none"> <li>• ↑ postprandial (water; 1h: +15 %, 2 h: +30 %) AnnexinV<sup>+</sup>/CD31<sup>+</sup>/CD42b<sup>-/+</sup> L-EVs</li> <li>• Red Wine consumption: ↓ meal-induced AnnexinV<sup>+</sup>/CD31<sup>+</sup>/CD42b<sup>-/+</sup> L-EVs compared to water (-83 %)</li> <li>• Coca: ↑ meal-induced AnnexinV<sup>+</sup>/CD31<sup>+</sup>/CD42b<sup>-/+</sup> L-EVs compared to water (+109 %)</li> </ul>
Eichner et al. Nutrients 2019 52		NA (US)	Obese prediabetic (PD, n= 17) and NGT (n= 8) volunteers Male:Female= 4:13 (PD), 1:7 (NGT) Age= 53.5 ± 4.1 (PD), 50.1 ± 5.1 (NGT) BMI= 32.1 ± 1.6 (PD), 33.2 ± 1.4 (NGT)	Oral Glucose Tolerance Test (a 75 g glucose intake that induced a 136 mg/dl glycaemia at peak, i.-e. 2 h)	Annexin V <sup>+</sup> EVs: ▪ CD31 <sup>+</sup> /CD41 <sup>+/-</sup> platelet EVs ▪ CD45 <sup>+</sup> /CD41 <sup>-</sup> , CD45 <sup>+</sup> leukocyte EVs ▪ CD105 <sup>+</sup> , CD31 <sup>+</sup> /CD41 <sup>-</sup> Endothelial EVs from Platelet-free plasma (17,000 g) by Flow cytometry (ImageStream MKII Amnis)	<ul style="list-style-type: none"> <li>• ↓ total EVs</li> <li>• ↓ CD31<sup>+</sup>/CD41<sup>+</sup> PEVs</li> <li>• ↓ CD31<sup>+</sup> EVs</li> <li>• ∅ CD45<sup>+</sup> LEVs</li> </ul>
Ferreira et al. Circulation 2004 53	Cross-over	NA (US)	Healthy volunteers (n= 18) Male:Female= 10:8 Age= 26 ± 3.8 BMI= 23 ± 2.3	I= High-fat meal (HF; 900 cal: 19 % from fat) C= Low-fat meal (LF; 900 cal: 0 % cal from fat)	<ul style="list-style-type: none"> <li>▪ CD31<sup>+</sup>/CD42b<sup>-</sup> endothelial L-EVs</li> <li>▪ CD31<sup>+</sup>/CD45<sup>+</sup> leukocyte L-EVs</li> </ul> From platelet-poor plasma (1,000 g) By flow cytometry (Coulter EPICS XL, Beckman)	<ul style="list-style-type: none"> <li>• C= ∅ effect of single Low-fat meal on postprandial E L-EV levels</li> <li>• I= ↑ postprandial (1 h: +39 %, 3 h: +70 %) CD31<sup>+</sup>/CD42b<sup>-</sup> Endothelial L-EVs</li> </ul>
Harrison et al. Eur J Appl Physiol 2009 54	Randomized Controlled	EU (Ireland)	Healthy active men (n= 8) Age= 26.9 ± 4.1 BMI= 26.0 ± 3.6	Oral fat tolerance test meal (1,450 kcal per 2 m <sup>2</sup> body surface: 60 % from fat, 34 % from CHO) preceded by a rested time or a prolonged exercise (EXC)	CD31 <sup>+</sup> /CD42b <sup>-</sup> endothelial L-EVs from Platelet-poor plasma (1,000 g) by Flow cytometry (FACScalibur, BD)	<ul style="list-style-type: none"> <li>• Test meal induces ↑ CD31<sup>+</sup>/CD42b<sup>-</sup> endothelial L-EVs from 2h to 6h after intake (+160 %)</li> <li>• ∅ of prior EXC on diet-induced EVs</li> </ul>
Jenkins et al. J Physiol 2011 55	Cross-over	NA (US)	Healthy active men (n= 10) Age= 27 ± 0.9 BMI= 24.6 ± 0.7	A single high-fat meal portioned to 386 g/m <sup>2</sup> body surface area (386 g= 1,362 kcal, 84 % from fat) ± prior endurance exercise	<ul style="list-style-type: none"> <li>▪ CD31<sup>+</sup>/CD42b<sup>-</sup> endothelial L-EVs</li> <li>▪ CD62E<sup>+</sup> endothelial L-EVs</li> </ul> From platelet-poor plasma (1,500 g) By flow cytometry (LSRII, BD)	<ul style="list-style-type: none"> <li>• ∅ effect of single high-fat meal on postprandial (4 h) endothelial L-EVs</li> <li>• Prior endurance exercise ↓ CD31<sup>+</sup>/CD42b<sup>-</sup> and CD62E<sup>+</sup> endothelial L-EVs (-50 %)</li> </ul>



Publication	Study design	Country	Participants	Intervention	Investigated EVs	Main results
-------------	--------------	---------	--------------	--------------	------------------	--------------

115 Table 2 (To be continued)

Publication	Study design	Country	Participants	Intervention	Investigated EVs	Main results
Michelsen et al. Thrombosis Res 2009 <sup>56</sup>	Controlled	EU (Norway)	Carotid atherosclerosis patients (n= 40, CAP) and matched healthy volunteers (n= 20, H) Male:Female= 19:21 (CAP) 12:8(H) Age= 65.4-72.8 (CAP), 66.6-70.1(H) BMI= 26.4-28.8 (CAP), 24.8-28.4(H)	Standardized tolerance fat test consisting in sour cream porridge providing 70 % of calories from fat (66 % saturated, 32 % monosaturated, 2 % PUFAs)	CD41 <sup>+</sup> /CD61 <sup>+</sup> platelet L-EVs From platelet-free plasma (11,000 g) By flow cytometry (Canto, BD)	↑ postprandial (4 h) total CD41 <sup>+</sup> /CD61 <sup>+</sup> L-EVs (+49 %)
Phang et al. JNB 2012 <sup>57</sup>	Controlled Single blinded	South Pacific (Australia)	Healthy volunteers (n= 30) Male:Female= 15:15 Age= 43.7 ± 1.5 BMI= 26.1 ± 0.6	A single dose of sunola oil (C), 1 g EPA (EPA:DHA= 5:1) or 1 g of DHA (EPA:DHA= 1:5)	AnnexinV <sup>+</sup> /CD41a <sup>+</sup> platelet L-EVs From platelet-free plasma (3,000 g) by flow cytometry (Canto, BD)	<ul style="list-style-type: none"> <li>• At baseline, ∅ effect gender on the number of platelet L-EVs</li> <li>• 24h after a single dose of supplementation: ∅ effect on AnnexinV<sup>+</sup>/CD41a<sup>+</sup> MP levels</li> <li>• Only EPA supplementation ↓ thrombin generation mediated by platelet L-EVs (-20 %)</li> </ul>
Spectre et al. Platelets 2019 <sup>58</sup>		EU (Sweden)	T2DM (n= 9) and T1DM (n= 11) patients Male:female= 8:1 (T2DM), 5:4(T1DM) Age= 55 (40-72, T1DM), 68 (60-76, T2DM) BMI= 23.5 (T1DM), 30 (T2DM)	A standardized meal (620 kcal: 30 % fat, 54 % CHO, 16 % protein)	Annexin V <sup>+</sup> L-EVs: <ul style="list-style-type: none"> <li>▪ CD41<sup>+</sup> ± CD62P<sup>+</sup> ± CD142<sup>+</sup> platelet L-EVs</li> <li>▪ CD144<sup>+</sup> or CD62e<sup>+</sup> endothelial L-EVs</li> <li>▪ CD14<sup>+</sup> monocyte L-EVs</li> <li>▪ CD142(TF)<sup>+</sup> L-EVs</li> </ul> from Platelet-free plasma (13,000 g) by Flow cytometry (Gallios, BD)	<ul style="list-style-type: none"> <li>• ↑ annexin V<sup>+</sup> L-EVs in T2DM and T1DM patients at 90min after meal (+40 %)</li> <li>• ↑ thrombin generation by postprandial L-EVs compared to pre-meal L-EVs</li> </ul>

Publication	Study design	Country	Participants	Intervention	Investigated EVs	Main results
Strohacker et al. Appl Physiol Nutr Metab 2012 59	Randomized Controlled	NA (US)	Healthy volunteers (n=8) Male:Female= 4:4 Age= 21 ± 3 BMI= 23.1 ± 3.92	Standardized test meal (1,070 kcal: 58 % from fat, 30 % CHO, 9 % proteins) ± prior endurance exercise or rest	CD31 <sup>+</sup> /CD42b <sup>-</sup> endothelial L-EVs From platelet-poor plasma (1,500 g) By flow cytometry (EasyCyte 6HT-2L, EMD Millipore)	<ul style="list-style-type: none"> <li>• Test meal: ↑ postprandial (1h: +50 %) CD31<sup>+</sup>/CD42b<sup>-</sup> endothelial L-EVs</li> <li>• Prior exercise blocks the postprandial ↑ of CD31<sup>+</sup>/CD42b<sup>-</sup> endothelial L-EVs</li> </ul>

116

117 **Table 2 (To be continued)**

Publication	Study design	Country	Participants	Intervention	Investigated EVs	Main results
Sustar et al. Lipids in Health & Disease 2011 46	Cross-over	EU (Slovenia)	Healthy volunteers (n=21) Male:Female= 11:10 Age= 31 ± 10 (M), 29 ± 13 (F) BMI=not reported	2 days of food rich in cholesterol, fat and carbohydrates. On day 2, a breakfast consisting of two eggs, bread and a dairy product (7 a.m.) and small meal consisting of a dairy product (10 a.m.)	CD31 <sup>+</sup> and CD42b <sup>-</sup> endothelial L-EVs CD31 <sup>+</sup> and CD42b <sup>+</sup> platelet L-EVs CD235 <sup>+</sup> erythrocyte L-EVs From plasma L-EVs (17,570 g pellet) By flow cytometry (Altra, Beckman)	<ul style="list-style-type: none"> <li>• postprandial total L-EVs (2 h: +52 %)</li> <li>• ∅ postprandial redistribution of L-EVs with respect to origin</li> </ul>
Sutherland et al. Metabol Clin Exp 2010 60	Randomized Cross-over Single blinded	South Pacific (New Zealand)	Healthy volunteers (n= 22) Male:Female= 13:9 Age= 40 ± 13 BMI= 25.3 ± 3.7	n-6 PUFAs-rich meals containing unheat sunflower oil (USO) or heated SO (HSO) (510 Kcal: 72 % from Fat ( <i>mainly</i> PUFAs), 25 % CHO, 2 % Proteins); C= saturated fat-rich meal containing cream (CR) (527 Kcal: 70 % from Fat ( <i>mainly</i> SAFAs and MUFAs), 27 % CHO, 4 % Proteins)	CD144 <sup>+</sup> CD62b <sup>-</sup> endothelial L-EVs From platelet-poor plasma (6,000 g) by flow cytometry (FACSCalibur, BD)	↑ postprandial (3 h: +20 %) CD144 <sup>+</sup> endothelial L-EVs after sunflower oil enriched meals but not after CR meal
Tamburrelli et al. Thrombosis & Haemostasis 2012 61		EU (Italia)	Subjects at different degree of CV risk (n= 61) Male:Female= 40:21 Age= 48.6 ± 13.1 BMI= 26.7 ± 3.94	A standardized fatty meal (675 kcal: 69 % from fat, 15 % CHO, 15 % proteins)	CD42b <sup>+</sup> L-EVs By flow cytometry (EPICS LX Flow, Beckman)	↑ postprandial (2 h: +150 %) CD42b <sup>+</sup> L-EVs in men, not in women
Tushuizen et al. Diabetes Care 2007 47	Not reported	EU (The Netherlands)	Caucasian men with T2DM (n= 15, T2DM) or healthy (n= 12, H; aged-matched) Age= 55 ± 2 (T2DM) BMI=not reported	Three consecutive isocaloric meals (breakfast, lunch and dinner; 900 kcal: 50 % from fat, 33 % CHO, 15 % protein)	AnnexinV <sup>+</sup> CD144 <sup>+</sup> endothelial L-EVs From plasma By flow cytometry (FACScan, BD)	<ul style="list-style-type: none"> <li>• At baseline, ↑ CD144<sup>+</sup> endothelial L-EVs in T2DM (+130 %)</li> <li>• 4h after the last meal, ↑ CD144<sup>+</sup> endothelial L-EVs in T2DM</li> </ul>

Publication	Study design	Country	Participants	Intervention	Investigated EVs	Main results
Tushuizen et al. J Thrombosis and Haemostasis 2006 <sup>48</sup>	Randomized Cross-over	EU (The Netherlands)	Healthy men (n= 17) Age= 25.4 ± 3 BMI= 23.6 ± 1.8	I= Two consecutive standardized meals (900 kcal: 56 % from fat, 25 % CHO, 13 % protein) as breakfast and 4h later as lunch C= fasting	<ul style="list-style-type: none"> <li>▪ CD61 for platelet L-EVs</li> <li>▪ CD62E, CD106 and CD144 for endothelial L-EVs</li> <li>▪ CD4, CD8 and CD14 for leukocyte L-EVs</li> </ul> From plasma By flow cytometry (FACScan, BD)	compared to healthy volunteers (+260 %)  I= ↑ total L-EVs compared to C (+100 % over the 8 h of the study) I= ↓ FMD

118 **Table 2 (To be continued)**

Publication	Study design	Country	Participants	Intervention	Investigated EVs	Main results
Tushuizen et al. Thrombosis Res 2012 <sup>62</sup>	Randomized Cross-over	EU (The Netherlands)	Healthy men (n= 12) Age= 26.0 ± 0.9 BMI= 23.9 ± 0.4	I=Two consecutive standardized meals (900 kcal: 56 % from fat, 25 % CHO, 13 % protein) as breakfast and 4h later as lunch C= fasting	AnnexinV <sup>+</sup> associated with <ul style="list-style-type: none"> <li>▪ CD61 for Platelet L-EVs</li> <li>▪ CD62E, CD106 and CD144 for endothelial L-EVs</li> <li>▪ CD4, CD8 and CD14 for leukocyte L-EVs</li> </ul> from plasma L-EVs (17,590 g pellet) By flow cytometry (FACScan, BD)	<ul style="list-style-type: none"> <li>• Over the postprandial period, ↑ erythrocyte-derived L-EVs (+220 %)</li> <li>After meals, ↑ phosphatidylcholine but not of phosphatidylserine in L-EVs compared to fasting</li> </ul>

119

120

121

122 Abbreviations

123 C: control diet, I: nutritional intervention, BMI: Body Mass Index, CV risk: Cardiovascular risk, T1/2DM: Type 1/2 Diabetes Mellitus, NA: North America, EU:

124 Europe, US: United States, CHO: carbohydrate, PUFAs: Poly Unsaturated Fatty Acid, EPA: EicosaPentaenoic Acid, DHA: DocosaHexaenoic Acid, NGT: Normo

125 Glucose Tolerance

## 2. The postprandial variation of circulating L-EVs

The response of L-EVs to the acute intake of different test meals (providing high dose of glucose, of saturated fat or enriched in polyunsaturated fatty acids) has been investigated during the postprandial period (Table 2)<sup>46-48, 51-62</sup>. The studies reported on the level of L-EVs assessed mainly 2-3 hours after the intake of the test meal in comparison to fasting conditions or to the consumption of a control meal. In healthy young volunteers, the consumption of a meal supplying 19-70 % energy from fat (mainly saturated fat) increased significantly the level of circulating L-EVs at 2 hours postprandially from 20 to 160 %<sup>48, 51, 53, 54, 59, 60, 62</sup>. Several subtypes of circulating L-EVs increased in response to fat intake: the endothelial L-EVs identified as CD31<sup>+</sup>-CD42b<sup>-</sup> (+50-160 %) <sup>53, 54, 59</sup>, annexin V<sup>+</sup>-CD31<sup>+</sup>-CD42b<sup>-</sup> (+30%) <sup>51</sup>, CD144<sup>+</sup> (+ 20 %) <sup>60</sup> and CD144<sup>+</sup>-CD62b<sup>-</sup> (+ 100-130 %) <sup>47, 48</sup> EVs, and the platelet-derived L-EVs characterized as annexin V<sup>+</sup>-CD31<sup>+</sup>-CD42b<sup>+</sup> <sup>51</sup> and CD41<sup>+</sup>-CD61<sup>+</sup> <sup>56</sup> EVs. Studies from Tushuizen et al. <sup>62</sup>, Sustar et al. <sup>46</sup> and Spectre et al. <sup>58</sup> also showed that all annexin V<sup>+</sup> L-EVs increased postprandially after a high fat meal. One study did not observe a variation of L-EV levels after a high fat meal while they used CD31-CD42b-CD62 markers to identify the endothelial L-EVs <sup>55</sup>. An acute increase of L-EV levels during the postprandial period was also observed in diabetic patients <sup>58</sup>, in individuals with cardiovascular risk <sup>61</sup> and in atherosclerotic patients <sup>56</sup>, all of them presenting already a higher fasting level of L-EVs when compared to healthy volunteers. It is noteworthy that the postprandial increase of L-EV levels had similar magnitude in individuals at CVD risk than in healthy volunteers <sup>56</sup>. Furthermore, based on the studies from Table 2, no correlation was found between the percentage of dietary fat and the magnitude of L-EV variation. Other nutrients provided by food such as carbohydrates (CHO) or proteins may affect the postprandial level of L-EVs. To our knowledge, no study has so far investigated the impact of protein intake on the postprandial EVs. Regarding CHO, *in vitro* studies showed that a high concentration of glucose increased the secretion of L-EVs from endothelial cells <sup>41, 63</sup>, leucocytes <sup>64, 65</sup>, trophoblasts <sup>40</sup> or mesangial cells <sup>66</sup>. In obese volunteers, Eichner et al. <sup>52</sup> reported that an oral glucose tolerance test, providing 75 g of glucose and resulting in a 136 mg/dL glycaemia at 2 hours, reduced the level of circulating L-EVs characterized in PFP. In addition, the postprandial level of CD31<sup>+</sup>-CD42b<sup>-</sup> endothelial L-EVs increased from 30 to 160 %, 2

152 hours after the intake of a test meal providing 50-60 % of fat and 30-34 % of CHO (mainly simple sugars)  
153 <sup>51, 54</sup>. Moreover, the study performed by Ferreira et al. <sup>53</sup> has demonstrated that a fat-free meal was not  
154 associated to an increased level of postprandial L-EVs compared to an isocaloric meal providing 19 % fat.  
155 Altogether, these data suggest that the percentage of CHO in the meal is not a determinant in the  
156 postprandial variation of L-EVs contrary to the fat content.

157 Diet may also provide some micronutrients (n-3 PUFAs) or microconstituents (polyphenols) that seem  
158 able to counteract the increase of postprandial EVs. The consumption of red wine, providing high amount  
159 of polyphenols, alleviated by 83 % the high-fat diet (HFD)-induced L-EVs <sup>51</sup>. Phang et al. <sup>57</sup> reported that 24  
160 hours after an acute intake of 1 g of n-3 PUFAs, the level of plasma annexin V<sup>+</sup>-CD41a<sup>+</sup> EVs was unchanged  
161 compared to a control meal. However, the intake of n-3 PUFAs reduced the capacity of these platelet-  
162 derived L-EVs to induce thrombin formation. Spectre et al. <sup>58</sup> reported that the postprandial annexin V<sup>+</sup> L-  
163 EVs induced a higher thrombin generation than pre-meal annexin V<sup>+</sup> L-EVs. Studies aiming at deciphering  
164 the biological function of postprandial EVs are scarce. Their functional activities could be predicted *in*  
165 *silico* by an enrichment-based bioinformatics analysis of the proteome and transcriptome of EVs, however  
166 the use of this approach is limited by the lack of data on protein content and nucleic acid content of the  
167 postprandial EVs.

168 To conclude, in so far as a meal provides saturated fats, its acute consumption is associated to a  
169 rapid rise of plasma L-EVs. In the absence of detailed pharmacokinetic data all over the postprandial  
170 phase, the transient character of the postprandial phase cannot be asserted to the EV rise. However, one  
171 can speculate that postprandial EVs temporary rise up as the clearance of endothelial- and platelet-  
172 derived L-EVs in the human circulation has been demonstrated to vary from 1 to 6 hours <sup>67, 68</sup>. Lastly,  
173 some dietary constituents such as dietary polyphenols and n-3 PUFAs modulate positively the biology of  
174 EVs during the postprandial phase, that is, either by preventing the increase of EV levels or attenuating  
175 their bioactivity.

176 **Table 3: Human intervention studies reporting the effects of (sub)chronic dietary intake on circulating EVs.** C: control diet; I: nutritional intervention.

Publication	Study design	Country	Participants	Dietary intervention	Duration (weeks)	Investigated EVs	Main results
Del Turco et al. Haematologica 2008 45	Randomized Controlled	EU (Denmarks)	Post-myocardial infraction patients (n= 21, I ; n= 21, C) Male:Female= 18:3 Age= 65 ± 5 (I), 62 ± 8 (C) BMI= not reported	I= 5.2g total n-3 FA (4.3 g EPA+DHA) C= Olive Oil	12	All AnnexinV <sup>+</sup> / TF <sup>+</sup> L-EVs ▪ CD61 <sup>+</sup> platelet L-EVs ▪ CD14 <sup>+</sup> monocyte L-EVs ▪ CD62E <sup>+</sup> endothelial L-EVs from 17,500 g pelleted plasma L-EVs	I=↓ CD61 <sup>+</sup> L-EVs, ↓ CD14 <sup>+</sup> L-EVs, ∅ CD62e <sup>+</sup> endothelial L-EVs, ∅ TF <sup>+</sup> L-EVs I= ↓ thrombin generation by L-EVs C=∅ L-EVs At baseline, ↑ total L-EVs in patients compared to healthy matched volunteers (n= 10)
Durrer et al. Nutrients 2019 69	Randomized Short-term Controller Cross-over	EU (UK)	Healthy men (n= 9) Age= 21 ± 3 BMI= 23.2 ± 2	○ A 7-day intervention on low-carbohydrate/high-fat diet (2417 ± 267 kcal: 71 % fat, 11 % CHO, 18 % protein) after 2 weeks of typical diet (2584 ± 456 kcal: 37 % fat, 46 % CHO, 17 % protein) ○ 75 g oral glucose tolerance test (oGTT) performed before and after nutritional interventional	1	▪ CD31 <sup>+</sup> /CD42b <sup>-</sup> endothelial L-EVs ▪ CD62E <sup>+</sup> endothelial L-EVs From platelet-poor plasma (1,500 g) By flow cytometry (LSRII, BD)	At fasting, no difference in L-EVs levels from LCHFD group compared to typical diet group ↑ post oGTT CD31 <sup>+</sup> /CD42b <sup>-</sup> and CD62E <sup>+</sup> endothelial L-EVs (1 h) in LCHFD group LCHFD: ↓ FMD
Eitan et al. Aging Cell 2017 70	Randomized Controlled	NA (US)	Prostate cancer patients (n= 38) Age= 59.26 ± 7.5 BMI= 30.45 ± 5.8	I= protein restriction diet (2856 ± 198 kcal: 31 % fat, 59 % CHO, 8 % protein) C= regular diet (2367 ± 444 Kcal: 37 % fat, 45 % CHO, 17 % protein)	4	L1CAM immunoprecipitated EVs from Precipitated total plasma EVs by NTA	I: ∅ EV size distribution, ∅ total EV concentration I: ↑ Leptin Receptor <sup>+</sup> /L1CAM <sup>+</sup> neuronal EVs, ↑ pSer312 IRS1 <sup>+</sup> /L1CAM <sup>+</sup> neuronal EVs
Francois et al. Am J Physiol Heart Circ Physiol 2018 71	Randomized Cross-over Controlled	NA (Canada)	T2DM volunteers (n= 16) Male:Female= 8:8 Age= 64 ± 8 BMI= 34.0± 8	2 isocaloric meals (500 kcal) ○ Low-fat control diet (CON: 20 % fat, 55 % CHO, 25 % protein) ○ low-carbohydrate high-fat diet (LC: 65 % Fat, 10 % CHO, 25 % protein) ○ LC with 15-min post-meal walks (LC-EX)	4 days	▪ CD62E <sup>+</sup> endothelial L-EVs ▪ CD62P <sup>+</sup> platelet L-EVs From platelet-free plasma (13,000 g) By flow cytometry (FACSAria III, BD)	LC : ↓ CD62E <sup>+</sup> endothelial L-EVs (- 50 %) ; ∅ CD62P <sup>+</sup> L-EVs LC-EX : ∅ CD62E <sup>+</sup> endothelial L-EVs ; ↓ CD62P <sup>+</sup> L-EVs (- 44 %) CON : ↑ CD62E <sup>+</sup> endothelial L-EVs (+ 56 %) ; ∅ CD62P <sup>+</sup> L-EVs

Publication	Study design	Country	Participants	Dietary intervention	Duration (weeks)	Investigated EVs	Main results
Gröne et al. JAF 2019 <sup>72</sup>	Randomized Double-blinded Controlled	EU (Germany)	Healthy men (n= 39) Age= 26 ± 3 (Young Group, n= 20), 60 ± 8 (Elderly Group, n= 19) BMI= 24.1 ± 2.3 (Young Group), 26.5 ± 3.2 (Elderly Group)	I= cocoa flavanol drink (CF, providing 450 mg of total flavanol, twice daily) C= nutrients-matched CF free drink	2	CD62e <sup>+</sup> endothelial L-EVs CD144 <sup>+</sup> endothelial L-EVs CD31 <sup>+</sup> /CD41 <sup>-</sup> endothelial L-EVs from Platelet-free plasma (10,000 g) by Flow cytometry (VERSE, BD)	I: ↓CD31 <sup>+</sup> /CD41 <sup>-</sup> endothelial L-EVs (Y: -52 %; E: -57 %), ↓CD144 <sup>+</sup> endothelial L-EVs (Y: -23 %; E: -21 %), ↓CD62e <sup>+</sup> endothelial L-EVs (Y: -35 %; E: -24 %) in Young and Elderly C: ↑CD31 <sup>+</sup> /CD41 <sup>-</sup> endothelial L-EVs (+52 %), ↑CD144 <sup>+</sup> endothelial L-EVs (+35 %), ↑CD62e <sup>+</sup> endothelial L-EVs (+57 %) in elderly vs young
Horn et al. BJN 2014 <sup>73</sup>	Randomized Double-blinded Cross-over	EU (Germany)	CAD patients (n= 16) Male:Female= 13:3 Age= 64 ± 3 BMI= 28.8 ± 1.8	I= high-cocoa flavanol drink (providing 375 mg of total flavanol) C= Low cocoa-flavanol drink (9 mg)	4	CD41 <sup>+</sup> platelet-derived L-EVs CD144 <sup>+</sup> endothelial L-EVs CD31 <sup>+</sup> /CD41 <sup>-</sup> endothelial L-EVs from Platelet-free plasma (10,000 g) by Flow cytometry (Canto II, BD)	I: ↓CD144 <sup>+</sup> endothelial L-EVs (-22 %), ↓CD31 <sup>+</sup> /CD41 <sup>-</sup> endothelial L-EVs (-39 %), ∅ CD41 <sup>+</sup> PL-EVs in CAD patients C: ↑ CD144 <sup>+</sup> (+ 490 %) and CD31 <sup>+</sup> /CD41 <sup>-</sup> (+ 30 %) endothelial L-EVs in CAD patients vs age-matched healthy volunteers
Marin et al. AJCN 2011 <sup>74</sup>	Randomised Cross-over	EU (Spain)	Healthy elderly volunteers (n= 20) Male:female=10:10 Age= 67.1 ± 4.52 BMI= 31.9 ± 5.50	3 diets providing 1910 Kcal/day - Mediterranean Diet (Met Diet): 38 % fat (24 % MUFAs, <10 % SFA), 47 % CHO, 15 % protein - SFA-rich diet: 38 % fat (12 % MUFAs, 22 % SFAs, 4 % PUFAs), 47 % CHO, 15 % protein - Low-fat high-carbohydrate diet enriched in n-3 PUFAs (CHO-ALA): <30 % fat (<12 % SFAs, 12 % MUFAs, 8 % PUFAs), 55 % CHO, 15 % protein	4	AnnexinV <sup>+</sup> CD31 <sup>+</sup> endothelial L-EVs CD144 <sup>+</sup> /CD62E <sup>+</sup> activated endothelial L-EVs from Platelet-free plasma (13,000 g) by Flow cytometry (FC500, Beckman)	I: Met Diet and CHO-ALA diet ↓ total (-60 %; -33 %), CD144 <sup>+</sup> /CD62e <sup>+</sup> (-76 %; -34 %) and annexinV <sup>+</sup> /CD31 <sup>+</sup> (-70 %; -25 %) endothelial L-EVs vs SFA diet I: Met Diet ↓ total (-40 %), CD144 <sup>+</sup> /CD62e <sup>+</sup> (-63 %) and annexinV <sup>+</sup> /CD31 <sup>+</sup> (-60 %) endothelial L-EVs vs CHO-ALA diet

Publication	Study design	Country	Participants	Dietary intervention	Duration (weeks)	Investigated EVs	Main results
McFarlin et al. JNB 2015 <sup>75</sup>	Randomized Controlled Cross-over	NA (US)	Healthy volunteers with normal weight (n= 10, N), over-weight (n= 7, O) or obesity (n=7, Ob) Age= 21 ± 2 (N), 22 ± 3 (O), 22 ± 3 (Ob) BMI= 21.6 ± 1.9 (N), 27.0 ± 1.4 (O), 34.9 ± 3.0 (Ob)	I= natural cocoa bars (supplying 13.6 mg catechin, 48 mg epicatechin, 640 mg total proanthocyanidins) C= placebo bars	4	CD144 <sup>+</sup> /CD42a <sup>-</sup> /CD45 <sup>-</sup> endothelial L-EVs from Platelet-free plasma (15,000 g) by Flow cytometry (FC500, Beckman)	I: ↓CD144 <sup>+</sup> /CD42a <sup>-</sup> /CD45 <sup>-</sup> L-EVs concentration in O (-13 %) and Ob (-31 %). C: ↑baseline CD144 <sup>+</sup> /CD42a <sup>-</sup> /CD45 <sup>-</sup> L-EVs concentration with ↑BMI (+21 % compared to O; +53 % compared to N)
Morel et al. Int J Obesity 2011 <sup>76</sup>	Cross-over	EU (France)	Obese women (n= 24) Age= 39 ± 10 BMI= 35 ± 4	I= diet restriction (600 kcal/day: 15 % Fat, 30 % CHO, 55 % Protein) for 1 month followed by a regular diet (1200 kcal/day: 10 % Fat, 60 % CHO, 30 % protein) for 1 month and a progressive normal intake (1 month)	12	AnnexinV <sup>+</sup> L-EVs CD11a <sup>+</sup> leukocyte L-EVs CD4 <sup>+</sup> lymphocyte L-EVs CD31 <sup>+</sup> CD41 <sup>-</sup> endothelial L-EVs CD41 <sup>+</sup> platelet L-EVs CD235 <sup>+</sup> erythrocyte L-EVs from Platelet-free plasma (13,000 g) by Flow cytometry (Gallios, BD)	1 month-diet restriction ↑ total AnnexinV <sup>+</sup> L-EVs (including CD41 <sup>+</sup> L-EVs, CD235 <sup>+</sup> L-EVs) I= ↓ CD4 <sup>+</sup> (-20 %), CD11a <sup>+</sup> (-28 %) and procoagulant-platelet derived L-EVs (-43 %)
Murakami et al. Thrombosis Research 2007 <sup>77</sup>	Randomized Controlled	Asia (Japan)	Obese (n= 49, O) and healthy non-obese (N= 37, N) volunteers Male:Female= 21:16 (N), 24/25 (O) Age= 49.2 ± 1.8 (N), 50.6 ± 1.4 (O) BMI= 22.8 ± 0.2 (N), 27.4 ± 0.3 (O)	I= energy restricted diet (1200 kcal/day for women; 1680 kcal/day for men) ± aerobic exercise 3 days/weeks (60 min/session)	12	CD41 <sup>+</sup> platelet L-EVs From platelet-rich plasma (200 g) By flow cytometry (FACScan, BD)	At baseline: ↑ CD41 <sup>+</sup> L-EVs in O (+97 %) I: energy restricted diet ↓ CD41 <sup>+</sup> L-EVs (-30 %)
Myette-Côté et al. Physiol 2018 <sup>78</sup>	Randomized Short-term Controller Cross-over	EU (UK)	T2DM volunteers (n= 11) Male:Female= 4:7 Age= 64 ± 8 BMI= 34.0 ± 8.0	○ Low-fat low-glycemic index diet (GL: 20 % fat, 55 % CHO, 25 % protein) ○ Low-carbohydrate high-fat diet (LC: 65 % Fat, 10 % CHO, 25 % protein) ○ LC with 15-min post-meal walks (LC-EX)	4days	CD14 <sup>+</sup> monocytes L-EVs CD45 <sup>+</sup> leukocyte L-EVs From platelet-free plasma (13,000 g) By flow cytometry (FACS Aria III, BD)	GL and LC ↓ both plasma CD14 <sup>+</sup> L-EVs (-70 %) and CD45 <sup>+</sup> LL-EVs (-63 %; 16 %; tendency)

181 Abbreviations: oGTT: oral Glucose Tolerance Test, MUFA: Mono Unsaturated Fatty Acid, SFA: saturated fatty acids.



Publication	Study design	Country	Participants	Dietary intervention	Duration (weeks)	Investigated EVs	Main results
Phang et al. Nutr CVD 2016 <sup>79</sup>	Randomized Controlled Double-blinded Cross-over	South Pacific (Australia)	Healthy volunteers (n=94) Male:Female= 43:51 Age= 39.6 ± 1.7 BMI= 24.6 ± 3.7	I= EPA rich oil (500:100 mg EPA:DHA) or DHA rich oil (100:500 mg EPA:DHA) C= sunola oil	4	AnnexinV <sup>+</sup> /CD41 <sup>+</sup> /CD62 <sup>+</sup> platelet L-EVs From platelet-free plasma (3,000 g) by flow cytometry (Canto, BD)	At baseline, ∅ effect gender on the number of endothelial L-EVs I= ∅ AnnexinV <sup>+</sup> /CD41 <sup>+</sup> /CD62 <sup>+</sup> L-EVs
Wekesa et al. Appl. Nutr 2016 <sup>80</sup>	Randomized Cross-over	EU (Ireland)	Overweight women (n=28) Age= 48.4 ± 0.6 BMI= 28.1 ± 2.7	I= low-carbohydrate diet (1228 Kcal: 48 % fat, 29 % CHO, 23 % protein) C=normal diet (1626 Kcal: 38 % fat, 44 % CHO, 18 % protein)	24	CD31 <sup>+</sup> /CD41 <sup>-</sup> Endothelial L-EVs CD144 <sup>+</sup> or CD146 <sup>+</sup> or CD105 <sup>+</sup> Endothelial L-EVs (namely endothelial L-EVs) from Platelet-poor plasma (13,000 g) by Flow cytometry (FC500, Beckman)	I= ↓ CD31 <sup>+</sup> /CD41 <sup>-</sup> endothelial L-EVs (-30 %), ∅ endothelial L-EVs
Wu et al. AJCN 2014 <sup>81</sup>	Randomized Controlled Double-blinded Cross-over	EU (UK)	Moderate CVD risk volunteers (n= 84) Male:Female= 29:55 Age= 45.8-49.3 BMI= 25.6-26.6	I= fish-oil supplementation providing 1.5g LC n-3 PUFAs C=corn-oil supplementation	8	CD31 <sup>+</sup> /CD42b <sup>-</sup> endothelial L-EVs CD31 <sup>+</sup> /CD42b <sup>+</sup> PL-EVs from platelet-poor plasma (1,000 g) by flow cytometry (FACSCalibur, BD)	I= ↓ CD31 <sup>+</sup> /CD42b <sup>-</sup> endothelial L-EVs (-10 %)
Zhang et al. MNFR 2014 <sup>82</sup>	Randomized Cross-over	EU (UK)	T2DM patients (n= 22) Mixed gender Age from 40 to 75 years BMI= not reported	○ oat-rich habitual diet (131 g/day, OAT) ○ standard dietary advice (SDA) ○ habitual diet (HAB)  Challenge meal (720 Kcal: 33 % fat, 53 % CHO, 14 % protein)	8	C61 <sup>+</sup> ± Fibrogen <sup>+</sup> or TF (CD142) <sup>+</sup> or CD62P <sup>+</sup> platelet L-EVs CD45 <sup>+</sup> ± CD14 <sup>+</sup> ± CD11b <sup>+</sup> leukocyte L-EVs from platelet-poor plasma (2,000 g) by flow cytometry (not detailed)	• OAT: ↓ Fibrogen <sup>+</sup> (-44 %) and TF <sup>+</sup> (-43 %) platelet L-EVs, CD11b <sup>+</sup> (-74 %) ML-EVs compared to HAB • SDA: ↓ Fibrogen <sup>+</sup> L-EVs compared to HAB (-47 %)  During the postprandial period after challenge meal: • Transient ↓ of leukocyte-derived L-EVs in all groups • ↓ of monocyte L-EVs and CD11b <sup>+</sup> L-EVs in OAT and SDA; ↑ in HAB
Weech et al. An. J. Clin. Nutr. 2018 <sup>83</sup>	Randomized, controlled, single-blind	EU (UK)	Men and Women with moderate CVD risk (n=190) Male:Female=82:108 Age=45 ± 1 BMI= 26.3 ± 0.5	I=replacement of 8% SFAs with MUFAs or n-6 PUFAs for 16 weeks		▪ CD31 <sup>+</sup> CD42b <sup>-</sup> for endothelial L-EVs ▪ CD31 <sup>+</sup> CD42b <sup>+</sup> for platelets L-EVs From platelet-poor plasma by flow cytometry (FACSCalibur, BD)	• Replacement by MUFAs: ↓ endothelial L-EVs (-47.3 %) and platelet L-EVs (-36.8 %)° • Replacement by n-6 PUFAs: ↓ endothelial L-EVs (-44.9 %) and platelet L-EVs (-39.1 %)° • SFA diet: ↑ endothelial L-EVs (+



184 **3. Chronic dietary interventions modulate plasma L-EVs at fasting**

185 Acute interventions have revealed that dietary intakes can drive the release of L-EVs during the  
186 postprandial period. Outside of this period (e.g., at fasting state), there still have detectable L-EVs in the  
187 circulation and have been of interest as reliable biomarkers for diagnosis and prognosis since a  
188 proportional increased level has been observed in several conditions, including ageing <sup>72, 84</sup>, physical  
189 activity <sup>85</sup>, metabolic disorders such as obesity <sup>12, 86</sup>, type 2 diabetes <sup>12, 13</sup> and metabolic syndrome <sup>87</sup>, and  
190 CVD <sup>88</sup>. Based on the established relationship between diet and health <sup>23</sup>, some research has been done to  
191 decipher the effects of (sub)chronic dietary interventions on plasma remnant EVs in different categories  
192 of population (e.g., healthy, young or normo-weighted persons, at risk, patients) (Table 3)<sup>45, 69-83</sup>. The  
193 efficiency of these interventions, lasting from 4 days to 24 weeks, has been assessed by comparing the  
194 plasma levels of L-EVs between the beginning (baseline) and the end of the study period or by comparing  
195 levels between study groups, depending on their design.

196 Two studies reported that diet restriction aiming at reducing the dietary energy intake of  
197 volunteers with a BMI over 25 kg/m<sup>2</sup> significantly reduced the level of circulating L-EVs. In obese women,  
198 a 600 kcal/day diet restriction for one month followed by two months of regular (1200 kcal/day) and  
199 normal diets results in lowering plasma levels of lymphocyte-derived (CD4<sup>+</sup>, -20 %), leukocyte-derived  
200 (CD11a<sup>+</sup>, -28 %) and procoagulant platelet-derived L-EVs (-43 %) <sup>76</sup>. In healthy middle-age volunteers, the  
201 increase of resident platelet-derived L-EVs (CD41<sup>+</sup>) associated to obesity can be attenuated by 30 % after  
202 12 weeks under an energy-restricted diet<sup>77</sup>. Another randomized controlled trial showed that a low  
203 protein diet (8%) administrated to prostate cancer patients did not affect the level of circulating cancer-  
204 derived L-EVs identified using L1CAM markers, but enriched some of the L-EV surface markers (Leptin  
205 Receptor and phospho-Ser-IRSII), supporting the effectiveness of the dietary intervention to affect level of  
206 plasma L-EVs<sup>70</sup>.

207 Dietary CHO, including sugars, starches, celluloses and gums serve as major energy sources of  
208 human diet. The physiological effects of dietary CHO are highly dependent on the rate and extent of  
209 digestion and absorption in the small intestine and fermentation in the large intestine by the gut

210 microbiota, these latter interactions being known to promote health. Thereby, the modulation of the CHO  
211 fraction could be useful to reach a healthier quality. Wekesa et al.<sup>80</sup> reported that a low-CHO diet  
212 decreases the level of circulating CD31<sup>+</sup>/CD41<sup>-</sup> endothelial L-EVs (30 %) in middle-aged over-weight  
213 healthy women. However, low-CHO content is often offset by an increased fat supply to maintain the  
214 energy content of the diet, that is why several studies have investigated the impact of a low CHO-high fat  
215 diet. Durrer et al.<sup>69</sup> did not observe any variation of CD31<sup>+</sup>/CD42b<sup>+</sup> and CD62<sup>+</sup> endothelial L-EVs in fasting  
216 plasma of young healthy volunteers after a 7 days- intervention on a low CHO-high fat diet. However,  
217 higher levels of plasma L-EVs were observed after a metabolic challenge consisting in an oral glucose  
218 tolerance test only in volunteers that consumed the low CHO-high fat diet. In type 2 diabetes volunteers,  
219 a low CHO-high fat diet reduced the level of plasma CD62<sup>+</sup> endothelial L-EVs (-45 %) <sup>71</sup> and leukocyte-  
220 derived L-EVs (-63 % of CD45<sup>+</sup> L-EVs, -70 % of CD14<sup>+</sup> L-EVs) <sup>78</sup>. In another study, the consumption for 8  
221 weeks of an oat-rich diet (providing complex CHO, extensively metabolized by the gut microbiota) has led  
222 to a lower level of fasting circulating fibrogen<sup>+</sup>-, TF<sup>+</sup>-CD61<sup>+</sup> platelet L-EVs (around -40 %) and of  
223 leukocytes-derived L-EVs after a challenge test meal in type 2 diabetes (T2DM) patients <sup>82</sup>. Taken  
224 together, these results highlight that dietary CHO content affects the basal level of circulating L-EVs. Most  
225 of the aforementioned studies did not specify the CHO quality used while a relationship between CHO  
226 quality and health have been demonstrated <sup>89</sup>, especially regarding CHO with a low glycaemic index and  
227 those poorly absorbable but highly metabolized by the gut microbiota. The nutritional interventions  
228 presented in this review provide low amount in total CHO <sup>69, 71, 80</sup> or high in low glycaemic index CHO <sup>78, 82</sup>  
229 and have been associated with a decrease in circulating L-EVs.

230 An intervention based on a Mediterranean diet, one of those peculiarity is to be rich in n-3 PUFAS  
231 (and in a diversity of plant food bioactives), reduce the level of circulating endothelial L-EVs identified as  
232 annexin V<sup>+</sup>-CD31<sup>+</sup> and CD144<sup>+</sup>-CD62e<sup>+</sup> vesicles in elderly volunteers <sup>74</sup>. In the same study, the authors  
233 have also demonstrated that a low-fat – high CHO diet enriched in n-3 PUFAs (8 %) modulated similarly  
234 the level of circulating endothelial L-EVs. In another randomized controlled trial, some subtypes of  
235 circulating L-EVs (namely CD61<sup>+</sup> platelet-derived and CD14<sup>+</sup> monocyte-derived L-EVs) present in high

236 amounts in post-myocardial infarction patients were reduced by a 12 weeks- supplementation with n-3  
237 PUFA <sup>45</sup>. Likewise, a fish-oil supplementation providing long chain n-3 PUFAs and saturated fatty acids  
238 replacement by MUFA or n-6 PUFAs reduced the circulating level of CD31<sup>+</sup>/CD42b<sup>-</sup> endothelial L-EVs  
239 and/or platelet L-EVs in volunteers with moderate risk of CVD <sup>81, 83</sup>. In contrast, in healthy middle-age  
240 volunteers, the 4-weeks diet enrichment in n-3 PUFAs failed to modulate the level of circulating annexin  
241 V<sup>+</sup>-CD41<sup>+</sup>-CD62<sup>+</sup> platelet L-EVs <sup>79</sup>.

242           Beyond their potential contribution to the observed modulatory effects of a Mediterranean Diet  
243 on circulating L-EVs <sup>74</sup>, the efficiency of polyphenols *per se* to modulate circulating L-EVs has also been  
244 investigated. Cocoa polyphenols have been of interest due to their well-known protective effects  
245 improving CV health <sup>90</sup>. Thus, McFarlin et al. <sup>75</sup> reported that a 4-weeks dietary supplementation with  
246 cocoa bars supplying flavanols and proanthocyanins (700 mg/d in total), reduced by 13% the  
247 concentration of endothelial L-EVs (identified as CD144<sup>+</sup>/CD42a<sup>-</sup>/CD45<sup>-</sup>) in over-weight young people.  
248 Similarly, the 52% higher level of CD31<sup>+</sup>/CD41<sup>-</sup> endothelial L-EVs observed in healthy elderly men  
249 compared to young men can be reduced by 50% after only 2 weeks of nutritional intervention supplying a  
250 cocoa flavanol rich drink twice a day (450 mg/daily dose) <sup>72</sup>. Lastly, the consumption of this cocoa flavanol  
251 rich drink for 4 weeks has been demonstrated to reduce significantly the levels of CD144<sup>+</sup> endothelial L-  
252 EVs (-22 %), CD31<sup>+</sup>/CD41<sup>-</sup> endothelial L-EVs (-39 %) but not of CD41<sup>+</sup> L-EVs in CAD patients <sup>73</sup>.

253           In conclusion, the analysis of these (sub)chronic intervention studies shows that dietary habits can  
254 affect the level of circulating L-EVs. Interventions aiming at providing a healthier diet, such as at low-  
255 glycaemic index or rich in n-3 PUFAs and plant food bioactives (e.g. polyphenols) appear efficient to  
256 reduce the level of circulating endothelial L-EVs and platelet-derived L-EVs in healthy volunteers or in  
257 patients with cardiometabolic disorders.

258

#### 259           **4. Dietary modulation of EVs: what potential underlying mechanisms of action?**

260           The release of S-EVs resulting the fusion of the MVB with the plasma membrane and the budding  
261 of L-EVs are mechanisms both highly regulated. They involved a wide range of factors which regulate (i)

262 deformability and bending of the membrane inside MVB or at the plasma membrane (i.e. the endosomal  
263 sorting complexes required for transport or ESCRT; the generation of ceramide; the tetraspanins),  
264 membrane lipid composition, intracellular trafficking (e.g. Rab GTPases and the soluble N-ethylmaleimide-  
265 sensitive factor activating protein receptors or SNAREs) and (ii) organization of the actomyosin  
266 cytoskeleton (Rho GTPases)<sup>8, 91-96</sup>. In the perspective that, as suggested by the present review of available  
267 data, the diet can impact EVs both in fasting and postprandial conditions, it would be interesting to  
268 understand how some macro-/micro-nutrients (glucose, amino acids, triglycerides, and n-3 PUFAs) and  
269 microconstituents (such as polyphenols, as main plant food bioactives) act to trigger physiological  
270 pathways controlling the biogenesis and/or the release of EVs.

271         The postprandial period is characterized among other metabolic changes by a transient increase  
272 in plasma glucose concentration whose magnitude depends on glucose load and on physiological state. *In*  
273 *vitro* studies have demonstrated that a moderate elevation in glucose concentration (from 1g/L (5.5 mM)  
274 to 1.9 g/L (11 mM)) or higher (up to 9g/L (50 mM)) increases the release of L-EVs by endothelial cells<sup>39, 41,</sup>  
275<sup>63</sup>, monocytes/leukocytes<sup>64, 65</sup> or renal mesangial cells<sup>66</sup>. However, Eichner et al.<sup>97</sup> observed that the level  
276 of plasma L-EVs (platelet-derived CD31<sup>+</sup>-CD41<sup>+</sup> EVs, endothelial-derived CD31<sup>+</sup>-CD41<sup>-</sup>/CD105<sup>+</sup> EVs) is  
277 lowered in obese adults with prediabetes at 2-h following administration of a single 75-g oral glucose load  
278 leading to 1.36 g/L plasma glucose. In contrast, an increased level of basal EVs has been reported in  
279 prediabetic individuals compared to individuals with normal glucose tolerance<sup>98</sup>. Consistently, chronic  
280 dietary interventions showed a direct correlation between CHO diet content and the level of plasma L-EVs  
281<sup>71, 78, 80</sup>. This suggests that dietary glucose can drive L-EV release. The underlying molecular mechanisms  
282 supporting the action of plasma glucose on L-EV release have not been properly explored. High glucose  
283 can activate several signalling pathways including mitogen-activated protein kinases (MAPK) and Rho-  
284 GTPases (as Rho A-ROCK)<sup>99-101</sup> that have been reported to target the production of EVs<sup>102, 103</sup>. The rise in  
285 glucose level also coincides with a rapid insulin secretion from pancreatic beta cells that exerts a  
286 hypoglycaemic action. To our knowledge, the effect of insulin on EV biogenesis has never been  
287 investigated. However, it is known that insulin regulates the intracellular vesicle trafficking machinery to

288 deliver the glucose transporter (GLUT4) to the cell surface and ensure glucose uptake. The insulin  
289 pathway engages small GTPases of RAB and ARF families (including the ADP-ribosylation factor 6, ARF6),  
290 tethering complexes and the vesicle fusion machinery (including the remodelling of the actin cytoskeleton  
291 and SNARE proteins)<sup>67, 104, 105</sup>. Some of these molecular actors are also involved in the biogenesis and the  
292 release of L-EVs<sup>8, 91-96</sup> suggesting that hyperinsulinemia may directly contribute to L-EV release.

293         The digestion of dietary proteins leads to a plasma increase of essential and branched-chain  
294 amino acids (BCAAs) from 40 to 120 min after protein intake<sup>106-108</sup>. The concomitant increase of  
295 aminoacidaemia and plasma EVs sustains a potential role of amino acids in the regulation of S-EV release.  
296 The main cellular amino acid sensors are the amino acid-sensitive kinase complex, mechanistic Target of  
297 Rapamycin Complex 1 (mTORC1) and the General Control Non-depressible Kinase 2 (GCN2)<sup>109-111</sup>. Briefly,  
298 under BCAA deficiency, the phosphorylate GCN2 contributes to the inhibition of mTORC1 and by  
299 consequence to the down regulation of protein synthesis. The low amino acids level is compensated by an  
300 enhance activity of autophagy or protein degradation mediated by the proteasome system to recycle  
301 damaged proteins back into BCAAs<sup>112</sup>. Evidences have disclosed that a crosstalk between proteolytic  
302 activities (e.g. autophagy, proteasome and lysosome) and the release of S-EVs, with a balance to a  
303 reduced EV biogenesis under starvation conditions<sup>113, 114</sup>. After a meal, the increase of aminoacidaemia  
304 and of insulin will restore the activity of mTORC1 contributing to alleviate the proteolytic activities and  
305 stimulate S-EV release<sup>115, 116</sup>. mTORC1 activation can also be driven by the phosphatidic acid of EV layers  
306 that has been detected in EV-like nanoparticles<sup>117</sup>. Specifically, in endothelial cells, the activation of  
307 mTORC1 contributes through reactive oxygen species (ROS) to impairment of the endothelial function<sup>118,</sup>  
308 <sup>119</sup>, which one feature is the increased release of endothelial L-EVs<sup>7</sup>. In addition, the endothelial  
309 dysfunction induced by a high-fat diet during the postprandial period can be attenuated by a dietary  
310 supply in proteins (mainly proteins rich in arginine and cysteine)<sup>120-122</sup>. Taken together, these  
311 observations support that dietary proteins can prevent EV release associated to postprandial cell  
312 dysfunctions. However, the lack of scientific evidence sustains the interest to explore the link between  
313 dietary BCAAs and the release of EVs.

314 Postprandial lipaemia is characterized by a rise in circulating free fatty acids (FFAs) and  
315 triglyceride-rich proteins (TRPs) that include intestine-derived chylomicrons and their remnants and liver-  
316 derived VLDLs <sup>123</sup>. The postprandial lipaemia peak occurs at 2 hours after meal intake, kinetic that  
317 depends on dietary factors (e.g. diet composition, lipid quantity, food structure), intrinsic factors (e.g.  
318 gender, age, genetic background, health status) and life style factors (e.g. physical activity, smoking) <sup>124</sup>,  
319 <sup>125</sup>. The postprandial FFAs can directly drive the release of S- and L-EVs <sup>126, 127</sup> acting on specific receptors  
320 such as the death receptor 5 (DR5) <sup>127</sup>. With TRPs, they can also bind to other receptors such as the toll-  
321 like receptor 4 (TLR-4), contributing to induce a transient postprandial low-grade inflammation <sup>128-131</sup>. In  
322 this way, postprandial lipaemia contributes to the development of a postprandial endothelial dysfunction  
323 <sup>128, 132</sup> associated with an enhanced release of EVs. In addition, metabolic changes associated to the  
324 postprandial period, mainly postprandial glucose and lipids, participate to generate oxidative stress <sup>133-135</sup>  
325 that sustains the postprandial development of low-grade inflammation state contributing to the release  
326 of EVs. Dietary n-3 PUFAs, in contrast to palmitic acids, participate lowering level of plasma EVs through a  
327 potent multi-level action that include their anti-inflammatory effect and their ability to modulate the  
328 mTOR pathway <sup>136, 137</sup>.

329 Some dietary microconstituents such as polyphenols peak as metabolites in the plasma during the  
330 postprandial period <sup>138</sup>. Dietary polyphenols have been reported to prevent the release of EVs but the  
331 underlying mechanism of action is unknown. Regarding their effects on endothelial-derived L-EVs, one  
332 can speculate that polyphenols act through their capacity at preserving endothelial function <sup>139</sup> and cell  
333 dynamics <sup>140</sup> to modulate the release of L-EVs. In addition, polyphenols have been demonstrated to  
334 counteract glucose-induced inhibition of autophagy in endothelial cells <sup>141</sup> suggesting that they can  
335 restore cellular homeostasis and by consequence L-EV secretion <sup>142</sup>. Polyphenols display potent mTOR  
336 modulator through the attenuation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, that can lead  
337 the regulation of L-EV synthesis and release as previously shown <sup>143</sup>.

338 Taken together, these sustain that diet-derived metabolites that circulate during the postprandial  
339 period can constitute modulators of EV secretion as summarized in Figure 1. Nevertheless, further



340 investigations are needed to decipher the underlying mechanisms of action. Furthermore, only the  
341 release of EVs has been considered here, while EV content that support EV bioactivity has never been  
342 investigated. Thus, another important question to address in future is how the diet can modulate the  
343 content of EVs, and by consequence their functions.

#### 344 **5. Food-derived EVs: can they affect human health?**

345 EVs from exogenous dietary sources such as milk or vegetables can be also found in bloodstream  
346 and affect homeostasis of the host or improve pathophysiological conditions. This is the particular  
347 interest taking in consideration the ability of EVs to protect some molecules with short half-life from  
348 degradation. For instance, EV-like nanoparticles from grapefruits and milk resist to digestion products of  
349 the host such as gastric enzymes and intestinal pancreatic and bile extract solution. Furthermore, these  
350 nanoparticles do not modify serum levels of interferon gamma (IFN- $\gamma$ ) and the liver enzymes in mice  
351 suggesting the lack of deleterious effects on inflammation <sup>23</sup>.

352 Interestingly, plant-derived EVs can display beneficial effects under pathological conditions due to  
353 the plant bioactive molecules that they carry, as recently reviewed <sup>43, 144, 145</sup>. Indeed, it has been shown  
354 that grapefruit-derived nanovesicles can be used as immune modulators in the digestive tract during  
355 colitis in mice. Thus, through the direct action on intestinal macrophages, these vesicles inhibit the  
356 production of IL-1 $\beta$  and TNF- $\alpha$  in these cells and allow the maintaining of intestinal macrophage  
357 homeostasis <sup>23</sup>. In the same pathology, broccoli-derived nanoparticles decrease the weight loss, the  
358 infiltration of inflammatory cells in the mucosa and the pro-inflammatory cytokine production <sup>30</sup>.  
359 Interestingly, broccoli-derived nanoparticles activate AMPK in dendritic cells leading to a dual effect  
360 associated to the prevention of dendritic cell activation and the induction of tolerant dendritic cells. Also,  
361 lemon-derived EVs display anti-tumor properties in several tumor cell lines by arresting cell proliferation  
362 of tumor cells *via* the induction of TRAIL-mediated cell death <sup>146</sup> and downregulating proteins implicated  
363 in the lipid metabolism pathway <sup>147</sup>. Dietary plant-derived EVs had also effects on lipid metabolism as  
364 illustrated by the fact that ginger-derived EVs can protect against the accumulation of lipid droplets  
365 during alcohol-induced liver damage <sup>147</sup> and lemon EVs reduce LDL cholesterol in healthy volunteers <sup>148</sup>.

366 Milk is another food source of EV-like nanoparticles that could modulate several functions of  
367 human milk-consumers triggering several host tissues<sup>149</sup>. In human food, milk and its derived products  
368 can be pasteurized and/or fermented. Milk-derived EVs numbers are not affected by pasteurization  
369 compared to other method of sterilization<sup>150, 151</sup>. Thus, pasteurized milk is a new source of large and small  
370 EVs for human consumers of western diet allowing the transfer of milk-derived microRNAs. These small  
371 EVs of pasteurized milk convey oncogenic micro RNAs (e.g., microRNA-21 and microRNA-148a) which  
372 both inhibit PTEN (Phosphatase and TENsin homolog) expression and drive mTORC1-mediated  
373 cancerogenesis<sup>152-154</sup>. In another study, the authors observed that bovine milk-EVs (orally administrated  
374 at 25 mg/kg) reduce primary tumor growth but accelerate metastasis in breast and pancreatic cancer  
375 mouse models<sup>155</sup>. The oral administration of milk-derived S-EVs have been also demonstrated to  
376 attenuate the severity of colitis<sup>156</sup> and of arthritis<sup>157</sup>. These beneficial effects have been partly associated  
377 to the ability of milk-derived S-EVs to reduce the expression of inflammatory cytokines (e.g. the monocyte  
378 chemo-attractant protein (MCP-1), inteleukin-6 and TNF- $\alpha$ ) and to up-regulate the expression of anti-  
379 inflammatory mediators such as the transforming growth factor beta (TGF- $\beta$ ). In addition, milk-derived S-  
380 EVs convey miRNAs that can act as epigenetic regulators contributing to the effects of these EVs on  
381 biological functions<sup>158</sup>. In addition, milk -derived S-EVs can drive some pathways such as the AMPK-  
382 mTORC1 activation<sup>152, 159</sup>, that can result in the release of EVs from the host recipient cells.. Furthermore,  
383 due to their small size EV-like nanoparticles from foods can probably cross the epithelial barrier including  
384 the blood brain barrier<sup>160</sup>. This hypothesis is supported by the loss of spatial learning and memory  
385 observed in mice fed a diet with bovine milk depleted in S-EVs for up to 20 weeks compared to mice  
386 consuming a complete diet<sup>161</sup> and the detection in brain of fluorescent-labelled milk S-EVs administered  
387 to adult mice through oral gavage<sup>162</sup>.

388 Together, these data underline the strength of EV-like nanoparticles from foods to impact on  
389 biological functions and the interest to consider these EVs as relevant dietary contributors on human  
390 health.

391

## 392 6. Diet-induced EVs: friends or foes for human health?

393 It is widely demonstrated that EVs are important mediators of cell-to-cell communication. EV-  
394 mediated intercellular communication begins by the recognition and the capture of circulating EVs by  
395 target cells<sup>92, 163</sup>, that is influenced by both EV surface markers and EV size. Information are transmitted  
396 from EVs to cells by acting at the cell membrane, with or without the delivery of their content. The  
397 mechanisms of uptake and cargo delivery into recipient cells are still incompletely understood. But  
398 evidences support that EVs drive phenotypic changes mostly by spreading the phenotypic features of  
399 donor cells to acceptor cells<sup>164</sup>. Thus, the pending question that is raised in the present review focuses on  
400 the biological function(s) of diet-induced EVs. Knowledge on this topic is still scarce and is constrained by  
401 the heterogenicity of circulating diet-induced EVs. As previously mentioned, diet modulates EV release  
402 mainly from endothelial cells, leukocytes and platelets. In addition to this board of cell source, it has been  
403 reported that cells release various subpopulations of EVs with distinct size, protein cargo and miRNAs  
404 content<sup>36, 165-168</sup>.

405 Spectre et al.<sup>58</sup>, who reported an increased level of annexin V<sup>+</sup> L-EV derived from endothelial  
406 cells, platelet and monocytes after a standard meal, have demonstrated that these EVs generate more  
407 thrombin than pre-meal EVs. In contrast, acute and chronic n-3 PUFA supplementation have been shown  
408 to lower plasma annexin V/TF<sup>+</sup> L-EV levels and their thrombin generation capacity<sup>45, 57</sup>. Endothelial-  
409 derived L-EVs carrying TF<sup>+</sup> and platelet-derived L-EVs exposing at their surface phosphatidylserine are  
410 known to be procoagulant and to increase the risk of venous thrombo-embolism<sup>169</sup>. Circulating L-EVs  
411 released in dyslipidaemia induced by a high-energy diet have been shown to contribute to inflammation  
412 and vascular damage by increasing the endothelial expression of intercellular adhesion molecule 1 (iCAM-  
413 1) and the production of reactive oxygen species and by reducing vascular relaxation of aortic rings<sup>21</sup>.  
414 These EVs also exert an antiatherogenic action through the reduction of caveolin 1 endothelial. Similarly,  
415 Jansen et al.<sup>170</sup> demonstrated that high glucose-induced L-EVs impair endothelial function as determined  
416 by a lower endothelial-dependent relaxation in EV-treated mice and by an increased adhesion of  
417 monocytes to L-EV-treated human coronary artery endothelial cells partly due to an up-regulation of

418 iCAM-1 and vCAM-1 in the treated cells. Similarly, L-EVs released from activated endothelial cells, such as  
419 those released during the transient diet-induced inflammation and endothelial dysfunction, exert a dual  
420 role. Luna et al.<sup>171</sup> reported that endothelial L-EVs induced by inflammation alter the function of  
421 endothelial cell progenitors whereas Mahmoud et al. showed that they reduce oxidative stress and  
422 prevent lipid-induced endothelial damage<sup>172</sup>. On another note, it has been observed in the Framingham  
423 Offspring cohort the association of circulating level of endothelial L-EVs (referred as CD31, CD144<sup>+</sup> EVs  
424 and known to reflect damaged endothelium) with the presence of cardiometabolic risk factors,  
425 particularly dyslipidaemia<sup>173</sup>.

426 Other EVs subtypes (e.g. from adipose tissues, skeletal muscles), not detected so far in human  
427 plasma in response to a meal intake or a chronic dietary supplementation, participate to attenuate  
428 glucose intolerance and to improve insulin resistance<sup>174-177</sup>. Wu et al.<sup>178</sup> demonstrated that S-EVs derived  
429 from liver and enriched in miR-130a contribute to the recovery of insulin resistance induced by an HFD in  
430 mice. A study by Kumar et al.<sup>179</sup> revealed that an HFD affect intestinal epithelial S-EVs that are enriched in  
431 phosphatidylcholine resulting in an inhibition of the insulin response in mice. The authors report the same  
432 alteration in lipid composition in S-EVs from patients with T2DM. Together, these results reveal that S-EVs  
433 are potential contributors to the development of insulin resistance and that diet can be an efficient  
434 strategy to attenuate their impact.

435 In absence of more investigations on the biological function(s) of diet-induced EVs, available data  
436 support that unbalanced diet could drive through metabolic changes (glycaemia, lipaemia, oxidative  
437 stress and related inflammation) the release of EVs that convey pro-inflammatory, pro-thrombotic and  
438 pro-atherogenic messages, these latter representing in case of chronicity an increased risk for health.  
439 However, this risk could be attenuated by an improved diet supplying protective micronutrients and plant  
440 food bioactives.

441

442 **Conclusion**

443 This review highlights the importance to consider diet as an important regulator both in  
444 postprandial and fasting conditions of EV biology and to develop further investigations to extend  
445 knowledge in this promising but still underexplored research field.

446 EVs modulated by diet have been identified using the same methods (i.e. surface markers) than for the  
447 detection of fasting EVs in patients with a diagnosis or prognosis purpose. By consequence, diet-  
448 associated EVs share similar phenotype characteristics with disease-associated EVs. Apart the “fast”  
449 feature during the postprandial period, the kinetic of release of diet-associated EVs has never been fully  
450 described. Consequently, their persistence in the bloodstream till a fasting state cannot be excluded. If so,  
451 this phenomenon could skew the use of fasting EVs as a reliable health biomarker and this aspect must be  
452 addressed properly. One bias of the methods used to explore human plasma EVs is to exclude S-EVs that  
453 may be modulated by diet and could be use as reliable nutritional biomarker as the L-EVs. Further, EV  
454 content, that is considered as a fingerprint of their cells of origin, has not been reported for diet-  
455 associated EVs. One critical question in this regard is how the cargo (e.g. proteins, miRNAs and lipids) of  
456 diet-associated EVs allow to differ them from EV released in health disturbances. In addition, an accurate  
457 characterization of diet-associated EV content will contribute to a better understanding of their biological  
458 functions. In 2021, Mantilla-Escalante et al.<sup>180</sup> report that the long-term consumption of a Mediterranean  
459 diet enriched in extra-virgin olive oil or nuts from participants of the PREDIMED study improves the  
460 number and modulates the miRNA profiles of circulating exosomes. This modulation could help to explain  
461 how such diet lead to beneficial health effects. Based on the biological functions reported for diseases  
462 associated-EVs or *in vitro* induced EVs sharing similar phenotype features, EVs induced after consumption  
463 of an unbalanced diet are assumed to constitute a risk factor for health, that could potentially be slow  
464 down by supplying diet with plant food bioactives protective for health. Answering these pending  
465 questions will contribute to substantiate the interest of EVs and their content as innovative tools to  
466 explore the relationship between nutrition and health.

467

468 **Acknowledgements**

469 We are grateful to Christine Morand (INRAE, UNH) for her valuable advice during the preparation of the  
470 manuscript.

471 This paper was supported and approved by INRAE.

472 Declaration of interest: none.

473

474 **Author contribution**

475 LEM performed literature search and analysis, and he wrote the manuscript. MCM contributed to the  
476 editing and reviewed the manuscript.

477

- 479 1. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular  
480 disease? A meta-analysis of prospective studies. *Arch Intern Med.* Oct 25 2004;164(19):2147-55.  
481 doi:10.1001/archinte.164.19.2147
- 482 2. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. *Am J*  
483 *Cardiol.* Feb 26 1998;81(4A):7B-12B. doi:10.1016/s0002-9149(98)00031-9
- 484 3. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High triglycerides/low high-density lipoprotein  
485 cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. *Am Heart J.* Jan  
486 2003;145(1):103-8. doi:10.1067/mhj.2003.45
- 487 4. Sniderman AD. Postprandial hypertriglyceridemia(s): time to enlarge our pathophysiologic  
488 perspective. *Eur J Clin Invest.* Nov 2000;30(11):935-7. doi:10.1046/j.1365-2362.2000.00733.x
- 489 5. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich  
490 remnant lipoproteins. *Clin Chem.* Jan 1995;41(1):153-8.
- 491 6. Cohn JS. Postprandial lipemia: emerging evidence for atherogenicity of remnant lipoproteins. *Can*  
492 *J Cardiol.* May 1998;14 Suppl B:18B-27B.
- 493 7. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial  
494 dysfunction. *Front Biosci.* May 1 2004;9:1118-35. doi:10.2741/1270
- 495 8. van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. *Nat*  
496 *Rev Mol Cell Biol.* Apr 2018;19(4):213-228. doi:10.1038/nrm.2017.125
- 497 9. Mallocci M, Perdomo L, Veerasamy M, Andriantsitohaina R, Simard G, Martinez MC. Extracellular  
498 Vesicles: Mechanisms in Human Health and Disease. *Antioxid Redox Signal.* Feb 20 2019;30(6):813-856.  
499 doi:10.1089/ars.2017.7265
- 500 10. La Marca V, Fierabracci A. Insights into the Diagnostic Potential of Extracellular Vesicles and Their  
501 miRNA Signature from Liquid Biopsy as Early Biomarkers of Diabetic Micro/Macrovascular Complications.  
502 *Int J Mol Sci.* Sep 14 2017;18(9)doi:10.3390/ijms18091974
- 503 11. Akbar N, Azzimato V, Choudhury RP, Aouadi M. Extracellular vesicles in metabolic disease.  
504 *Diabetologia.* Dec 2019;62(12):2179-2187. doi:10.1007/s00125-019-05014-5
- 505 12. Pardo F, Villalobos-Labra R, Sobrevia B, Toledo F, Sobrevia L. Extracellular vesicles in obesity and  
506 diabetes mellitus. *Mol Aspects Med.* Apr 2018;60:81-91. doi:10.1016/j.mam.2017.11.010
- 507 13. Zhou F, Huang L, Qu SL, et al. The emerging roles of extracellular vesicles in diabetes and diabetic  
508 complications. *Clin Chim Acta.* Oct 2019;497:130-136. doi:10.1016/j.cca.2019.07.032
- 509 14. Kim A, Shah AS, Nakamura T. Extracellular Vesicles: A Potential Novel Regulator of Obesity and Its  
510 Associated Complications. *Children (Basel).* Nov 15 2018;5(11)doi:10.3390/children5110152
- 511 15. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from  
512 circulating and vascular cells in regulating vascular function. *American journal of physiology Heart and*  
513 *circulatory physiology.* Mar 2005;288(3):H1004-9. doi:10.1152/ajpheart.00842.2004
- 514 16. Lin ZB, Ci HB, Li Y, et al. Endothelial microparticles are increased in congenital heart diseases and  
515 contribute to endothelial dysfunction. *J Transl Med.* Jan 4 2017;15(1):4. doi:10.1186/s12967-016-1087-2
- 516 17. Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular vesicles in coronary artery disease.  
517 *Nat Rev Cardiol.* May 2017;14(5):259-272. doi:10.1038/nrcardio.2017.7
- 518 18. Crewe C, Joffin N, Rutkowski JM, et al. An Endothelial-to-Adipocyte Extracellular Vesicle Axis  
519 Governed by Metabolic State. *Cell.* Oct 18 2018;175(3):695-708 e13. doi:10.1016/j.cell.2018.09.005
- 520 19. Ogino N, Takahashi H, Nagaoka K, et al. Possible contribution of hepatocyte secretion to the  
521 elevation of plasma exosomal arginase-1 in high-fat diet-fed mice. *Life Sci.* Aug 1 2021;278:119588.  
522 doi:10.1016/j.lfs.2021.119588
- 523 20. Povero D, Eguchi A, Li H, et al. Circulating extracellular vesicles with specific proteome and liver  
524 microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. *PLoS One.*  
525 2014;9(12):e113651. doi:10.1371/journal.pone.0113651
- 526 21. Ousmaal MEF, Gaceb A, Khene MA, et al. Circulating microparticles released during dyslipidemia  
527 may exert deleterious effects on blood vessels and endothelial function. *J Diabetes Complications.* Oct  
528 2020;34(10):107683. doi:10.1016/j.jdiacomp.2020.107683

- 529 22. Heinrich LF, Andersen DK, Cleasby ME, Lawson C. Long-term high fat feeding of rats results in  
530 increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells. *The*  
531 *British journal of nutrition*. Jun 14 2015;113(11):1704-11. doi:10.1017/S0007114515001117
- 532 23. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all causes,  
533 cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective  
534 cohort studies. *BMJ*. Jul 29 2014;349:g4490. doi:10.1136/bmj.g4490
- 535 24. Morand C, Barber-Chamoux N, Monfoulet LE, Milenkovic D. Dietary (Poly)Phenols and Vascular  
536 Health. In: Halbwirth H, Stich K, Cheynier V, Quideau S, eds. *Recent Advances in Polyphenol Research,*  
537 *Volume 6*. John Wiley & Sons Ltd.; 2019:chap 5.
- 538 25. Krga I, Milenkovic D, Morand C, Monfoulet LE. An update on the role of nutrigenomic modulations  
539 in mediating the cardiovascular protective effect of fruit polyphenols. *Food Funct*. Sep 14 2016;7(9):3656-  
540 76. doi:10.1039/c6fo00596a
- 541 26. Chiva-Blanch G, Badimon L. Effects of Polyphenol Intake on Metabolic Syndrome: Current  
542 Evidences from Human Trials. *Oxid Med Cell Longev*. 2017;2017:5812401. doi:10.1155/2017/5812401
- 543 27. Lopez Andres N, Tesse A, Regnault V, et al. Increased microparticle production and impaired  
544 microvascular endothelial function in aldosterone-salt-treated rats: protective effects of polyphenols.  
545 *PLoS One*. 2012;7(7):e39235. doi:10.1371/journal.pone.0039235
- 546 28. Munir J, Lee M, Ryu S. Exosomes in Food: Health Benefits and Clinical Relevance in Diseases. *Adv*  
547 *Nutr*. May 1 2020;11(3):687-696. doi:10.1093/advances/nmz123
- 548 29. Rome S. Biological properties of plant-derived extracellular vesicles. *Food Funct*. Feb 20  
549 2019;10(2):529-538. doi:10.1039/c8fo02295j
- 550 30. Deng Z, Rong Y, Teng Y, et al. Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating  
551 Dendritic Cell AMP-Activated Protein Kinase. *Mol Ther*. Jul 5 2017;25(7):1641-1654.  
552 doi:10.1016/j.ymthe.2017.01.025
- 553 31. Zhang M, Viennois E, Prasad M, et al. Edible ginger-derived nanoparticles: A novel therapeutic  
554 approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer.  
555 *Biomaterials*. Sep 2016;101:321-40. doi:10.1016/j.biomaterials.2016.06.018
- 556 32. Konoshenko MY, Lekchnov EA, Vlassov AV, Laktionov PP. Isolation of Extracellular Vesicles:  
557 General Methodologies and Latest Trends. *Biomed Res Int*. 2018;2018:8545347.  
558 doi:10.1155/2018/8545347
- 559 33. Suarez H, Gamez-Valero A, Reyes R, et al. A bead-assisted flow cytometry method for the semi-  
560 quantitative analysis of Extracellular Vesicles. *Sci Rep*. Sep 12 2017;7(1):11271. doi:10.1038/s41598-017-  
561 11249-2
- 562 34. Görgens A, Nolan JP. Aiming to Compare Apples to Apples: Analysis of Extracellular Vesicles and  
563 other Nano-sized Particles by Flow Cytometry. *Cytometry Part A*.  
564 2020;doi:<https://doi.org/10.1002/cyto.a.24173>
- 565 35. van Ierssel SH, Hoymans VY, Van Craenenbroeck EM, et al. Endothelial microparticles (EMP) for  
566 the assessment of endothelial function: an in vitro and in vivo study on possible interference of plasma  
567 lipids. *PLoS One*. 2012;7(2):e31496. doi:10.1371/journal.pone.0031496
- 568 36. Dozio V, Sanchez JC. Characterisation of extracellular vesicle-subsets derived from brain  
569 endothelial cells and analysis of their protein cargo modulation after TNF exposure. *J Extracell Vesicles*.  
570 2017;6(1):1302705. doi:10.1080/20013078.2017.1302705
- 571 37. Tucher C, Bode K, Schiller P, et al. Extracellular Vesicle Subtypes Released From Activated or  
572 Apoptotic T-Lymphocytes Carry a Specific and Stimulus-Dependent Protein Cargo. *Front Immunol*.  
573 2018;9:534. doi:10.3389/fimmu.2018.00534
- 574 38. Haraszti RA, Didiot MC, Sapp E, et al. High-resolution proteomic and lipidomic analysis of  
575 exosomes and microvesicles from different cell sources. *J Extracell Vesicles*. 2016;5:32570.  
576 doi:10.3402/jev.v5.32570
- 577 39. Li S, Zhan JK, Wang YJ, et al. Exosomes from hyperglycemia-stimulated vascular endothelial cells  
578 contain versican that regulate calcification/senescence in vascular smooth muscle cells. *Cell Biosci*.  
579 2019;9:1. doi:10.1186/s13578-018-0263-x



- 580 40. Rice GE, Scholz-Romero K, Sweeney E, et al. The Effect of Glucose on the Release and Bioactivity  
581 of Exosomes From First Trimester Trophoblast Cells. *J Clin Endocrinol Metab.* Oct 2015;100(10):E1280-8.  
582 doi:10.1210/jc.2015-2270
- 583 41. Wu XM, Gao YB, Cui FQ, Zhang N. Exosomes from high glucose-treated glomerular endothelial  
584 cells activate mesangial cells to promote renal fibrosis. *Biol Open.* Apr 15 2016;5(4):484-91.  
585 doi:10.1242/bio.015990
- 586 42. Osterman CJ, Lynch JC, Leaf P, et al. Curcumin Modulates Pancreatic Adenocarcinoma Cell-Derived  
587 Exosomal Function. *PLoS One.* 2015;10(7):e0132845. doi:10.1371/journal.pone.0132845
- 588 43. Soleti R, Andriantsitohaina R, Martinez MC. Impact of polyphenols on extracellular vesicle levels  
589 and effects and their properties as tools for drug delivery for nutrition and health. *Arch Biochem Biophys.*  
590 Apr 15 2018;644:57-63. doi:10.1016/j.abb.2018.03.004
- 591 44. Taverna S, Fontana S, Monteleone F, et al. Curcumin modulates chronic myelogenous leukemia  
592 exosomes composition and affects angiogenic phenotype via exosomal miR-21. *Oncotarget.* May 24  
593 2016;7(21):30420-39. doi:10.18632/oncotarget.8483
- 594 45. Del Turco S, Basta G, Lazzarini G, et al. Effect of the administration of n-3 polyunsaturated fatty  
595 acids on circulating levels of microparticles in patients with a previous myocardial infarction.  
596 *Haematologica.* Jun 2008;93(6):892-9. doi:10.3324/haematol.11845
- 597 46. Sustar V, Bedina-Zavec A, Stukelj R, et al. Post-prandial rise of microvesicles in peripheral blood of  
598 healthy human donors. *Lipids Health Dis.* Mar 21 2011;10:47. doi:10.1186/1476-511X-10-47
- 599 47. Tushuizen ME, Nieuwland R, Rustemeijer C, et al. Elevated endothelial microparticles following  
600 consecutive meals are associated with vascular endothelial dysfunction in type 2 diabetes. *Diabetes care.*  
601 Mar 2007;30(3):728-30. doi:10.2337/dc06-1473
- 602 48. Tushuizen ME, Nieuwland R, Scheffer PG, Sturk A, Heine RJ, Diamant M. Two consecutive high-fat  
603 meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy  
604 men. *Journal of thrombosis and haemostasis : JTH.* May 2006;4(5):1003-10. doi:10.1111/j.1538-  
605 7836.2006.01914.x
- 606 49. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor  
607 exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2  
608 diabetes mellitus. *Circulation.* Nov 5 2002;106(19):2442-7. doi:10.1161/01.cir.0000036596.59665.c6
- 609 50. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. *Int J*  
610 *Biol Sci.* 2013;9(10):1057-69. doi:10.7150/ijbs.7502
- 611 51. Bulut D, Jelich U, Dacanay-Schwarz R, Mugge A. Red wine ingestion prevents microparticle  
612 formation after a single high-fat meal--a crossover study in healthy humans. *Journal of cardiovascular*  
613 *pharmacology.* Jun 2013;61(6):489-94. doi:10.1097/FJC.0b013e31828ac882
- 614 52. Eichner NZM, Gilbertson NM, Musante L, et al. An Oral Glucose Load Decreases Postprandial  
615 Extracellular Vesicles in Obese Adults with and without Prediabetes. *Nutrients.* Mar 8  
616 2019;11(3)doi:10.3390/nu11030580
- 617 53. Ferreira AC, Peter AA, Mendez AJ, et al. Postprandial hypertriglyceridemia increases circulating  
618 levels of endothelial cell microparticles. *Circulation.* Dec 7 2004;110(23):3599-603.  
619 doi:10.1161/01.CIR.0000148820.55611.6B
- 620 54. Harrison M, Murphy RP, O'Connor PL, et al. The endothelial microparticle response to a high fat  
621 meal is not attenuated by prior exercise. *European journal of applied physiology.* Jul 2009;106(4):555-62.  
622 doi:10.1007/s00421-009-1050-5
- 623 55. Jenkins NT, Landers RQ, Thakkar SR, et al. Prior endurance exercise prevents postprandial  
624 lipaemia-induced increases in reactive oxygen species in circulating CD31+ cells. *The Journal of physiology.*  
625 Nov 15 2011;589(Pt 22):5539-53. doi:10.1113/jphysiol.2011.215277
- 626 56. Michelsen AE, Noto AT, Brodin E, Mathiesen EB, Brosstad F, Hansen JB. Elevated levels of platelet  
627 microparticles in carotid atherosclerosis and during the postprandial state. *Thrombosis research.* Apr  
628 2009;123(6):881-6. doi:10.1016/j.thromres.2008.10.016
- 629 57. Phang M, Lincz L, Seldon M, Garg ML. Acute supplementation with eicosapentaenoic acid reduces  
630 platelet microparticle activity in healthy subjects. *The Journal of nutritional biochemistry.* Sep  
631 2012;23(9):1128-33. doi:10.1016/j.jnutbio.2011.06.006

632 58. Spectre G, Mobarrez F, Stalesen R, et al. Meal intake increases circulating procoagulant  
633 microparticles in patients with type 1 and type 2 diabetes mellitus. *Platelets*. 2019;30(3):348-355.  
634 doi:10.1080/09537104.2018.1445837

635 59. Strohacker K, Breslin WL, Carpenter KC, Davidson TR, Agha NH, McFarlin BK. Moderate-intensity,  
636 premeal cycling blunts postprandial increases in monocyte cell surface CD18 and CD11a and endothelial  
637 microparticles following a high-fat meal in young adults. *Applied physiology, nutrition, and metabolism =*  
638 *Physiologie appliquee, nutrition et metabolisme*. Jun 2012;37(3):530-9. doi:10.1139/h2012-034

639 60. Sutherland WH, de Jong SA, Hessian PA, Williams MJ. Ingestion of native and thermally oxidized  
640 polyunsaturated fats acutely increases circulating numbers of endothelial microparticles. *Metabolism:*  
641 *clinical and experimental*. Mar 2010;59(3):446-53. doi:10.1016/j.metabol.2009.07.033

642 61. Tamburrelli C, Gianfagna F, D'Imperio M, et al. Postprandial cell inflammatory response to a  
643 standardised fatty meal in subjects at different degree of cardiovascular risk. *Thrombosis and*  
644 *haemostasis*. Mar 2012;107(3):530-7. doi:10.1160/TH11-09-0674

645 62. Tushuizen ME, Diamant M, Peypers EG, et al. Postprandial changes in the phospholipid  
646 composition of circulating microparticles are not associated with coagulation activation. *Thrombosis*  
647 *research*. Jul 2012;130(1):115-21. doi:10.1016/j.thromres.2011.09.003

648 63. Bammert TD, Hijmans JG, Reiakvam WR, et al. High glucose derived endothelial microparticles  
649 increase active caspase-3 and reduce microRNA-Let-7a expression in endothelial cells. *Biochem Biophys*  
650 *Res Commun*. Nov 18 2017;493(2):1026-1029. doi:10.1016/j.bbrc.2017.09.098

651 64. Thom SR, Bhopale VM, Yu K, Huang W, Kane MA, Margolis DJ. Neutrophil microparticle  
652 production and inflammasome activation by hyperglycemia due to cytoskeletal instability. *J Biol Chem*.  
653 Nov 3 2017;292(44):18312-18324. doi:10.1074/jbc.M117.802629

654 65. Li M, Zhang X, Yu J, Wu X, Sun L. Monocyte-Derived Procoagulant Microvesicles Induced by High  
655 Glucose Can Be Attenuated by the Antioxidant N-Acetyl-L-Cysteine, Partly Through the P38/MAPK  
656 Pathway. *Metab Syndr Relat Disord*. Dec 2017;15(10):521-526. doi:10.1089/met.2017.0089

657 66. Ettelaie C, Su S, Li C, Collier ME. Tissue factor-containing microparticles released from mesangial  
658 cells in response to high glucose and AGE induce tube formation in microvascular cells. *Microvasc Res*.  
659 Nov 2008;76(3):152-60. doi:10.1016/j.mvr.2008.07.007

660 67. Augustine D, Ayers LV, Lima E, et al. Dynamic release and clearance of circulating microparticles  
661 during cardiac stress. *Circ Res*. Jan 3 2014;114(1):109-13. doi:10.1161/CIRCRESAHA.114.301904

662 68. Rank A, Nieuwland R, Crispin A, et al. Clearance of platelet microparticles in vivo. *Platelets*.  
663 2011;22(2):111-6. doi:10.3109/09537104.2010.520373

664 69. Durrer C, Lewis N, Wan Z, Ainslie PN, Jenkins NT, Little JP. Short-Term Low-Carbohydrate High-Fat  
665 Diet in Healthy Young Males Renders the Endothelium Susceptible to Hyperglycemia-Induced Damage, An  
666 Exploratory Analysis. *Nutrients*. Feb 26 2019;11(3)doi:10.3390/nu11030489

667 70. Eitan E, Tosti V, Suire CN, et al. In a randomized trial in prostate cancer patients, dietary protein  
668 restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles. *Aging cell*. Dec  
669 2017;16(6):1430-1433. doi:10.1111/acel.12657

670 71. Francois ME, Myette-Cote E, Bammert TD, et al. Carbohydrate restriction with postmeal walking  
671 effectively mitigates postprandial hyperglycemia and improves endothelial function in type 2 diabetes.  
672 *American journal of physiology Heart and circulatory physiology*. Jan 1 2018;314(1):H105-H113.  
673 doi:10.1152/ajpheart.00524.2017

674 72. Grone M, Sansone R, Hoffken P, et al. Cocoa Flavanols Improve Endothelial Functional Integrity in  
675 Healthy Young and Elderly Subjects. *Journal of agricultural and food chemistry*. Aug 12  
676 2019;doi:10.1021/acs.jafc.9b02251

677 73. Horn P, Amabile N, Angeli FS, et al. Dietary flavanol intervention lowers the levels of endothelial  
678 microparticles in coronary artery disease patients. *The British journal of nutrition*. Apr 14  
679 2014;111(7):1245-52. doi:10.1017/S0007114513003693

680 74. Marin C, Ramirez R, Delgado-Lista J, et al. Mediterranean diet reduces endothelial damage and  
681 improves the regenerative capacity of endothelium. *The American journal of clinical nutrition*. Feb  
682 2011;93(2):267-74. doi:10.3945/ajcn.110.006866

683 75. McFarlin BK, Venable AS, Henning AL, et al. Natural cocoa consumption: Potential to reduce  
684 atherogenic factors? *The Journal of nutritional biochemistry*. Jun 2015;26(6):626-32.  
685 doi:10.1016/j.jnutbio.2014.12.015

686 76. Morel O, Luca F, Grunebaum L, et al. Short-term very low-calorie diet in obese females improves  
687 the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished  
688 release of platelet and leukocyte-derived microparticles. *International journal of obesity*. Dec  
689 2011;35(12):1479-86. doi:10.1038/ijo.2011.19

690 77. Murakami T, Horigome H, Tanaka K, et al. Impact of weight reduction on production of platelet-  
691 derived microparticles and fibrinolytic parameters in obesity. *Thrombosis research*. 2007;119(1):45-53.  
692 doi:10.1016/j.thromres.2005.12.013

693 78. Myette-Cote E, Durrer C, Neudorf H, et al. The effect of a short-term low-carbohydrate, high-fat  
694 diet with or without postmeal walks on glycemic control and inflammation in type 2 diabetes: a  
695 randomized trial. *American journal of physiology Regulatory, integrative and comparative physiology*. Dec  
696 1 2018;315(6):R1210-R1219. doi:10.1152/ajpregu.00240.2018

697 79. Phang M, Thorne RF, Alkhatatbeh MJ, Garg ML, Lincz LF. Circulating CD36+ microparticles are not  
698 altered by docosahexaenoic or eicosapentaenoic acid supplementation. *Nutrition, metabolism, and  
699 cardiovascular diseases : NMCD*. Mar 2016;26(3):254-60. doi:10.1016/j.numecd.2015.12.003

700 80. Wekesa AL, Doyle LM, Fitzmaurice D, et al. Influence of a low-carbohydrate diet on endothelial  
701 microvesicles in overweight women. *Applied physiology, nutrition, and metabolism = Physiologie  
702 appliquee, nutrition et metabolisme*. May 2016;41(5):522-7. doi:10.1139/apnm-2015-0507

703 81. Wu SY, Mayneris-Perxachs J, Lovegrove JA, Todd S, Yaqoob P. Fish-oil supplementation alters  
704 numbers of circulating endothelial progenitor cells and microparticles independently of eNOS genotype.  
705 *The American journal of clinical nutrition*. Nov 2014;100(5):1232-43. doi:10.3945/ajcn.114.088880

706 82. Zhang X, McGeoch SC, Megson IL, et al. Oat-enriched diet reduces inflammatory status assessed  
707 by circulating cell-derived microparticle concentrations in type 2 diabetes. *Molecular nutrition & food  
708 research*. Jun 2014;58(6):1322-32. doi:10.1002/mnfr.201300820

709 83. Weech M, Altowaijri H, Mayneris-Perxachs J, et al. Replacement of dietary saturated fat with  
710 unsaturated fats increases numbers of circulating endothelial progenitor cells and decreases numbers of  
711 microparticles: findings from the randomized, controlled Dietary Intervention and VAScular function  
712 (DIVAS) study. *The American journal of clinical nutrition*. Jun 1 2018;107(6):876-882.  
713 doi:10.1093/ajcn/nqy018

714 84. Panagiotou N, Neytchev O, Selman C, Shiels PG. Extracellular Vesicles, Ageing, and Therapeutic  
715 Interventions. *Cells*. Aug 18 2018;7(8)doi:10.3390/cells7080110

716 85. Wilhelm EN, Mourout L, Rakobowchuk M. Exercise-Derived Microvesicles: A Review of the  
717 Literature. *Sports Med*. Sep 2018;48(9):2025-2039. doi:10.1007/s40279-018-0943-z

718 86. Stepanian A, Bourguignat L, Hennou S, et al. Microparticle increase in severe obesity: not related  
719 to metabolic syndrome and unchanged after massive weight loss. *Obesity (Silver Spring)*. Nov  
720 2013;21(11):2236-43. doi:10.1002/oby.20365

721 87. Martinez MC, Andriantsitohaina R. Extracellular Vesicles in Metabolic Syndrome. *Circ Res*. May 12  
722 2017;120(10):1674-1686. doi:10.1161/CIRCRESAHA.117.309419

723 88. Chong SY, Lee CK, Huang C, et al. Extracellular Vesicles in Cardiovascular Diseases: Alternative  
724 Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers. *Int J Mol Sci*. Jul 3  
725 2019;20(13)doi:10.3390/ijms20133272

726 89. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and  
727 human health: a series of systematic reviews and meta-analyses. *Lancet*. Feb 2 2019;393(10170):434-445.  
728 doi:10.1016/S0140-6736(18)31809-9

729 90. Crozier SJ, Hurst WJ. Cocoa Polyphenols and Cardiovascular Health. In: Ronald Ross Watson  
730 VRPaSZ, ed. *Polyphenols in Human Health and Disease*. 2014:1077-1085:chap 83.

731 91. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes  
732 and other extracellular vesicles. *Annu Rev Cell Dev Biol*. 2014;30:255-89. doi:10.1146/annurev-cellbio-  
733 101512-122326

734 92. Mathieu M, Martin-Jaular L, Lavieu G, Thery C. Specificities of secretion and uptake of exosomes  
735 and other extracellular vesicles for cell-to-cell communication. *Nat Cell Biol.* Jan 2019;21(1):9-17.  
736 doi:10.1038/s41556-018-0250-9

737 93. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating  
738 microparticles. *Arterioscler Thromb Vasc Biol.* Jan 2011;31(1):15-26. doi:10.1161/ATVBAHA.109.200956

739 94. E. L. Andaloussi S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging  
740 therapeutic opportunities. *Nat Rev Drug Discov.* May 2013;12(5):347-57. doi:10.1038/nrd3978

741 95. Sedgwick AE, D'Souza-Schorey C. The biology of extracellular microvesicles. *Traffic.* May  
742 2018;19(5):319-327. doi:10.1111/tra.12558

743 96. Juan T, Furthauer M. Biogenesis and function of ESCRT-dependent extracellular vesicles. *Semin  
744 Cell Dev Biol.* Feb 2018;74:66-77. doi:10.1016/j.semcdb.2017.08.022

745 97. Eichner NZM, Erdbrugger U, Malin SK. Extracellular Vesicles: A Novel Target for Exercise-Mediated  
746 Reductions in Type 2 Diabetes and Cardiovascular Disease Risk. *J Diabetes Res.* 2018;2018:7807245.  
747 doi:10.1155/2018/7807245

748 98. Giannella A, Radu CM, Franco L, et al. Circulating levels and characterization of microparticles in  
749 patients with different degrees of glucose tolerance. *Cardiovasc Diabetol.* Sep 19 2017;16(1):118.  
750 doi:10.1186/s12933-017-0600-0

751 99. Yang J, Han Y, Chen C, et al. EGCG attenuates high glucose-induced endothelial cell inflammation  
752 by suppression of PKC and NF-kappaB signaling in human umbilical vein endothelial cells. *Life Sci.* Mar 21  
753 2013;92(10):589-97. doi:10.1016/j.lfs.2013.01.025

754 100. Srivastava AK. High glucose-induced activation of protein kinase signaling pathways in vascular  
755 smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review). *Int J  
756 Mol Med.* Jan 2002;9(1):85-9.

757 101. Sheu ML, Ho FM, Yang RS, et al. High glucose induces human endothelial cell apoptosis through a  
758 phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. *Arterioscler Thromb Vasc Biol.* Mar  
759 2005;25(3):539-45. doi:10.1161/01.ATV.0000155462.24263.e4

760 102. Li B, Antonyak MA, Zhang J, Cerione RA. RhoA triggers a specific signaling pathway that generates  
761 transforming microvesicles in cancer cells. *Oncogene.* Nov 8 2012;31(45):4740-9.  
762 doi:10.1038/onc.2011.636

763 103. Curtis AM, Wilkinson PF, Gui M, Gales TL, Hu E, Edelberg JM. p38 mitogen-activated protein  
764 kinase targets the production of proinflammatory endothelial microparticles. *Journal of thrombosis and  
765 haemostasis : JTH.* Apr 2009;7(4):701-9. doi:10.1111/j.1538-7836.2009.03304.x

766 104. Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. *Nat Rev Mol  
767 Cell Biol.* May 23 2012;13(6):383-96. doi:10.1038/nrm3351

768 105. Tong P, Khayat ZA, Huang C, Patel N, Ueyama A, Klip A. Insulin-induced cortical actin remodeling  
769 promotes GLUT4 insertion at muscle cell membrane ruffles. *J Clin Invest.* Aug 2001;108(3):371-81.  
770 doi:10.1172/JCI12348

771 106. Alcock RD, Shaw GC, Tee N, Burke LM. Plasma Amino Acid Concentrations After the Ingestion of  
772 Dairy and Collagen Proteins, in Healthy Active Males. *Front Nutr.* 2019;6:163.  
773 doi:10.3389/fnut.2019.00163

774 107. Farnfield MM, Trenerry C, Carey KA, Cameron-Smith D. Plasma amino acid response after  
775 ingestion of different whey protein fractions. *Int J Food Sci Nutr.* Sep 2009;60(6):476-86.  
776 doi:10.1080/09637480701833465

777 108. Kurien A, Sharma N, Marathe M, et al. Acute Effect of a Protein Supplement on Targeted Plasma  
778 Amino Acid Profile among Healthy Asian Indians: A Randomized Controlled Trial. *J Nutr Metab.*  
779 2020;2020:8946820. doi:10.1155/2020/8946820

780 109. Goberdhan DC, Wilson C, Harris AL. Amino Acid Sensing by mTORC1: Intracellular Transporters  
781 Mark the Spot. *Cell Metab.* Apr 12 2016;23(4):580-9. doi:10.1016/j.cmet.2016.03.013

782 110. Lushchak O, Strilbytska OM, Yurkevych I, Vaiserman AM, Storey KB. Implications of amino acid  
783 sensing and dietary protein to the aging process. *Exp Gerontol.* Jan 2019;115:69-78.  
784 doi:10.1016/j.exger.2018.11.021

785 111. Averous J, Lambert-Langlais S, Mesclon F, et al. GCN2 contributes to mTORC1 inhibition by leucine  
786 deprivation through an ATF4 independent mechanism. *Sci Rep.* Jun 14 2016;6:27698.  
787 doi:10.1038/srep27698

788 112. Puertollano R. mTOR and lysosome regulation. *F1000Prime Rep.* 2014;6:52. doi:10.12703/P6-52

789 113. Baixauli F, Lopez-Otin C, Mittelbrunn M. Exosomes and autophagy: coordinated mechanisms for  
790 the maintenance of cellular fitness. *Front Immunol.* 2014;5:403. doi:10.3389/fimmu.2014.00403

791 114. Eitan E, Suire C, Zhang S, Mattson MP. Impact of lysosome status on extracellular vesicle content  
792 and release. *Ageing Res Rev.* Dec 2016;32:65-74. doi:10.1016/j.arr.2016.05.001

793 115. Fan SJ, Kroeger B, Marie PP, et al. Glutamine deprivation alters the origin and function of cancer  
794 cell exosomes. *EMBO J.* Aug 17 2020;39(16):e103009. doi:10.15252/embj.2019103009

795 116. Zou W, Lai M, Zhang Y, et al. Exosome Release Is Regulated by mTORC1. *Adv Sci (Weinh).* Feb 6  
796 2019;6(3):1801313. doi:10.1002/advs.201801313

797 117. Wang X, Devaiah SP, Zhang W, Welti R. Signaling functions of phosphatidic acid. *Prog Lipid Res.*  
798 May 2006;45(3):250-78. doi:10.1016/j.plipres.2006.01.005

799 118. Reho JJ, Guo DF, Morgan DA, Rahmouni K. mTORC1 (Mechanistic Target of Rapamycin Complex 1)  
800 Signaling in Endothelial and Smooth Muscle Cells Is Required for Vascular Function. *Hypertension.* Dec 28  
801 2020:HYPERTENSIONAHA12014708. doi:10.1161/HYPERTENSIONAHA.120.14708

802 119. Reho JJ, Guo DF, Rahmouni K. Mechanistic Target of Rapamycin Complex 1 Signaling Modulates  
803 Vascular Endothelial Function Through Reactive Oxygen Species. *J Am Heart Assoc.* May 7  
804 2019;8(9):e010662. doi:10.1161/JAHA.118.010662

805 120. Lin CC, Tsai WC, Chen JY, Li YH, Lin LJ, Chen JH. Supplements of L-arginine attenuate the effects of  
806 high-fat meal on endothelial function and oxidative stress. *Int J Cardiol.* Jul 21 2008;127(3):337-41.  
807 doi:10.1016/j.ijcard.2007.06.013

808 121. Magne J, Huneau JF, Tsikas D, et al. Rapeseed protein in a high-fat mixed meal alleviates  
809 postprandial systemic and vascular oxidative stress and prevents vascular endothelial dysfunction in  
810 healthy rats. *J Nutr.* Sep 2009;139(9):1660-6. doi:10.3945/jn.109.107441

811 122. Westphal S, Taneva E, Kastner S, et al. Endothelial dysfunction induced by postprandial lipemia is  
812 neutralized by addition of proteins to the fatty meal. *Atherosclerosis.* Apr 2006;185(2):313-9.  
813 doi:10.1016/j.atherosclerosis.2005.06.004

814 123. Klop B, Proctor SD, Mamo JC, Botham KM, Castro Cabezas M. Understanding postprandial  
815 inflammation and its relationship to lifestyle behaviour and metabolic diseases. *Int J Vasc Med.*  
816 2012;2012:947417. doi:10.1155/2012/947417

817 124. Desmarchelier C, Borel P, Lairon D, Maraninchi M, Valero R. Effect of Nutrient and Micronutrient  
818 Intake on Chylomicron Production and Postprandial Lipemia. *Nutrients.* Jun 8  
819 2019;11(6)doi:10.3390/nu11061299

820 125. Dias CB, Moughan PJ, Wood LG, Singh H, Garg ML. Postprandial lipemia: factoring in lipemic  
821 response for ranking foods for their healthiness. *Lipids Health Dis.* Sep 18 2017;16(1):178.  
822 doi:10.1186/s12944-017-0568-5

823 126. Cobbs A, Chen X, Zhang Y, et al. Saturated fatty acid stimulates production of extracellular vesicles  
824 by renal tubular epithelial cells. *Mol Cell Biochem.* Aug 2019;458(1-2):113-124. doi:10.1007/s11010-019-  
825 03535-6

826 127. Hirsova P, Ibrahim SH, Krishnan A, et al. Lipid-Induced Signaling Causes Release of Inflammatory  
827 Extracellular Vesicles From Hepatocytes. *Gastroenterology.* Apr 2016;150(4):956-67.  
828 doi:10.1053/j.gastro.2015.12.037

829 128. Alipour A, Elte JW, van Zaanen HC, Rietveld AP, Cabezas MC. Postprandial inflammation and  
830 endothelial dysfunction. *Biochem Soc Trans.* Jun 2007;35(Pt 3):466-9. doi:10.1042/BST0350466

831 129. de Vries MA, Klop B, Janssen HW, Njo TL, Westerman EM, Castro Cabezas M. Postprandial  
832 inflammation: targeting glucose and lipids. *Adv Exp Med Biol.* 2014;824:161-70. doi:10.1007/978-3-319-  
833 07320-0\_12

834 130. Dimina L, Mariotti F. The Postprandial Appearance of Features of Cardiometabolic Risk: Acute  
835 Induction and Prevention by Nutrients and Other Dietary Substances. *Nutrients.* Aug 21  
836 2019;11(9)doi:10.3390/nu11091963

837 131. Herieka M, Erridge C. High-fat meal induced postprandial inflammation. *Molecular nutrition &*  
838 *food research*. Jan 2014;58(1):136-46. doi:10.1002/mnfr.201300104

839 132. de Koning EJ, Rabelink TJ. Endothelial function in the post-prandial state. *Atheroscler Suppl*. May  
840 2002;3(1):11-6. doi:10.1016/s1567-5688(01)00008-3

841 133. Sies H, Stahl W, Sevanian A. Nutritional, dietary and postprandial oxidative stress. *J Nutr*. May  
842 2005;135(5):969-72. doi:10.1093/jn/135.5.969

843 134. Tsai WC, Li YH, Lin CC, Chao TH, Chen JH. Effects of oxidative stress on endothelial function after a  
844 high-fat meal. *Clin Sci (Lond)*. Mar 2004;106(3):315-9. doi:10.1042/CS20030227

845 135. Ursini F, Sevanian A. Postprandial oxidative stress. *Biol Chem*. Mar-Apr 2002;383(3-4):599-605.  
846 doi:10.1515/BC.2002.062

847 136. Shirooie S, Nabavi SF, Dehpour AR, et al. Targeting mTORs by omega-3 fatty acids: A possible  
848 novel therapeutic strategy for neurodegeneration? *Pharmacol Res*. Sep 2018;135:37-48.  
849 doi:10.1016/j.phrs.2018.07.004

850 137. Yasuda M, Tanaka Y, Kume S, et al. Fatty acids are novel nutrient factors to regulate mTORC1  
851 lysosomal localization and apoptosis in podocytes. *Biochim Biophys Acta*. Jul 2014;1842(7):1097-108.  
852 doi:10.1016/j.bbdis.2014.04.001

853 138. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and  
854 bioavailability. *The American journal of clinical nutrition*. May 2004;79(5):727-47.  
855 doi:10.1093/ajcn/79.5.727

856 139. Yamagata K, Tagami M, Yamori Y. Dietary polyphenols regulate endothelial function and prevent  
857 cardiovascular disease. *Nutrition*. Jan 2015;31(1):28-37. doi:10.1016/j.nut.2014.04.011

858 140. Monfoulet LE, Mercier S, Bayle D, et al. Curcumin modulates endothelial permeability and  
859 monocyte transendothelial migration by affecting endothelial cell dynamics. *Free Radic Biol Med*. Nov  
860 2017;112:109-120. doi:10.1016/j.freeradbiomed.2017.07.019

861 141. Zhang PW, Tian C, Xu FY, et al. Green Tea Polyphenols Alleviate Autophagy Inhibition Induced by  
862 High Glucose in Endothelial Cells. *Biomed Environ Sci*. Jul 2016;29(7):524-8. doi:10.3967/bes2016.069

863 142. Salimi L, Akbari A, Jabbari N, et al. Synergies in exosomes and autophagy pathways for cellular  
864 homeostasis and metastasis of tumor cells. *Cell Biosci*. 2020;10:64. doi:10.1186/s13578-020-00426-y

865 143. Pazoki-Toroudi H, Amani H, Ajami M, et al. Targeting mTOR signaling by polyphenols: A new  
866 therapeutic target for ageing. *Ageing Res Rev*. Nov 2016;31:55-66. doi:10.1016/j.arr.2016.07.004

867 144. Urzi O, Raimondo S, Alessandro R. Extracellular Vesicles from Plants: Current Knowledge and  
868 Open Questions. *Int J Mol Sci*. May 20 2021;22(10)doi:10.3390/ijms22105366

869 145. Kameli N, Dragojlovic-Kerkache A, Savelkoul P, Stassen FR. Plant-Derived Extracellular Vesicles:  
870 Current Findings, Challenges, and Future Applications. *Membranes (Basel)*. May 29  
871 2021;11(6)doi:10.3390/membranes11060411

872 146. Raimondo S, Naselli F, Fontana S, et al. Citrus limon-derived nanovesicles inhibit cancer cell  
873 proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death. *Oncotarget*. Aug  
874 14 2015;6(23):19514-27. doi:10.18632/oncotarget.4004

875 147. Raimondo S, Saieva L, Cristaldi M, Monteleone F, Fontana S, Alessandro R. Label-free quantitative  
876 proteomic profiling of colon cancer cells identifies acetyl-CoA carboxylase alpha as antitumor target of  
877 Citrus limon-derived nanovesicles. *J Proteomics*. Feb 20 2018;173:1-11. doi:10.1016/j.jprot.2017.11.017

878 148. Raimondo S, Nikolic D, Conigliaro A, et al. Preliminary Results of CitraVes Effects on Low Density  
879 Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label  
880 Study. *Metabolites*. Apr 27 2021;11(5)doi:10.3390/metabo11050276

881 149. Zempleni J, Sukreet S, Zhou F, Wu D, Mutai E. Milk-Derived Exosomes and Metabolic Regulation.  
882 *Annu Rev Anim Biosci*. Feb 15 2019;7:245-262. doi:10.1146/annurev-animal-020518-115300

883 150. Melnik BC, Schmitz G. Pasteurized non-fermented cow's milk but not fermented milk is a  
884 promoter of mTORC1-driven aging and increased mortality. *Ageing Res Rev*. May 2021;67:101270.  
885 doi:10.1016/j.arr.2021.101270

886 151. Kleinjan M, van Herwijnen MJ, Libregts SF, van Neerven RJ, Feitsma AL, Wauben MH. Regular  
887 Industrial Processing of Bovine Milk Impacts the Integrity and Molecular Composition of Extracellular  
888 Vesicles. *J Nutr*. Jun 1 2021;151(6):1416-1425. doi:10.1093/jn/nxab031

889 152. Melnik BC. Milk exosomal miRNAs: potential drivers of AMPK-to-mTORC1 switching in beta-cell  
890 de-differentiation of type 2 diabetes mellitus. *Nutr Metab (Lond)*. 2019;16:85. doi:10.1186/s12986-019-  
891 0412-1

892 153. Melnik BC, Schmitz G. Exosomes of pasteurized milk: potential pathogens of Western diseases. *J*  
893 *Transl Med*. Jan 3 2019;17(1):3. doi:10.1186/s12967-018-1760-8

894 154. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. *Cell*. Mar 9  
895 2017;168(6):960-976. doi:10.1016/j.cell.2017.02.004

896 155. Samuel M, Fonseka P, Sanwlani R, et al. Oral administration of bovine milk-derived extracellular  
897 vesicles induces senescence in the primary tumor but accelerates cancer metastasis. *Nat Commun*. Jun 24  
898 2021;12(1):3950. doi:10.1038/s41467-021-24273-8

899 156. Reif S, Elbaum-Shiff Y, Koroukhov N, Shilo I, Musseri M, Golan-Gerstl R. Cow and Human Milk-  
900 Derived Exosomes Ameliorate Colitis in DSS Murine Model. *Nutrients*. Aug 26  
901 2020;12(9)doi:10.3390/nu12092589

902 157. Arntz OJ, Pieters BC, Oliveira MC, et al. Oral administration of bovine milk derived extracellular  
903 vesicles attenuates arthritis in two mouse models. *Molecular nutrition & food research*. Sep  
904 2015;59(9):1701-12. doi:10.1002/mnfr.201500222

905 158. Melnik BC, Schmitz G. MicroRNAs: Milk's epigenetic regulators. *Best Pract Res Clin Endocrinol*  
906 *Metab*. Aug 2017;31(4):427-442. doi:10.1016/j.beem.2017.10.003

907 159. Melnik BC. Milk--A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent  
908 Translation. *Int J Mol Sci*. Jul 27 2015;16(8):17048-87. doi:10.3390/ijms160817048

909 160. Saint-Pol J, Gosselet F, Duban-Deweere S, Pottiez G, Karamanos Y. Targeting and Crossing the  
910 Blood-Brain Barrier with Extracellular Vesicles. *Cells*. Apr 1 2020;9(4)doi:10.3390/cells9040851

911 161. Mutai E, Zhou F, Zempleni J. Depletion of Dietary Bovine Milk Exosomes Impairs Sensorimotor  
912 Gating and Spatial Learning in C57BL/6 Mice. *The FASEB Journal*. 2018;31.1(150.4)doi:  
913 [https://doi.org/10.1096/fasebj.31.1\\_supplement.150.4](https://doi.org/10.1096/fasebj.31.1_supplement.150.4)

914 162. Manca S, Upadhyaya B, Mutai E, et al. Milk exosomes are bioavailable and distinct microRNA  
915 cargos have unique tissue distribution patterns. *Sci Rep*. Jul 27 2018;8(1):11321. doi:10.1038/s41598-018-  
916 29780-1

917 163. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. *J Extracell*  
918 *Vesicles*. 2014;3doi:10.3402/jev.v3.24641

919 164. de Jong OG, Verhaar MC, Chen Y, et al. Cellular stress conditions are reflected in the protein and  
920 RNA content of endothelial cell-derived exosomes. *J Extracell Vesicles*. 2012;1doi:10.3402/jev.v1i0.18396

921 165. Alexandru N, Constantin A, Nemezc M, et al. Hypertension Associated With Hyperlipidemia  
922 Induced Different MicroRNA Expression Profiles in Plasma, Platelets, and Platelet-Derived Microvesicles;  
923 Effects of Endothelial Progenitor Cell Therapy. *Front Med (Lausanne)*. 2019;6:280.  
924 doi:10.3389/fmed.2019.00280

925 166. Durcin M, Fleury A, Taillebois E, et al. Characterisation of adipocyte-derived extracellular vesicle  
926 subtypes identifies distinct protein and lipid signatures for large and small extracellular vesicles. *J Extracell*  
927 *Vesicles*. 2017;6(1):1305677. doi:10.1080/20013078.2017.1305677

928 167. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release  
929 phenotypically and quantitatively distinct microparticles in activation and apoptosis. *Thrombosis research*.  
930 Feb 15 2003;109(4):175-80. doi:10.1016/s0049-3848(03)00064-1

931 168. Willms E, Johansson HJ, Mager I, et al. Cells release subpopulations of exosomes with distinct  
932 molecular and biological properties. *Sci Rep*. Mar 2 2016;6:22519. doi:10.1038/srep22519

933 169. Zara M, Guidetti GF, Camera M, et al. Biology and Role of Extracellular Vesicles (EVs) in the  
934 Pathogenesis of Thrombosis. *Int J Mol Sci*. Jun 11 2019;20(11)doi:10.3390/ijms20112840

935 170. Jansen F, Yang X, Franklin BS, et al. High glucose condition increases NADPH oxidase activity in  
936 endothelial microparticles that promote vascular inflammation. *Cardiovasc Res*. Apr 1 2013;98(1):94-106.  
937 doi:10.1093/cvr/cvt013

938 171. Luna C, Carmona A, Alique M, Carracedo J, Ramirez R. TNFalpha-Damaged-HUVECs Microparticles  
939 Modify Endothelial Progenitor Cell Functional Activity. *Front Physiol*. 2015;6:395.  
940 doi:10.3389/fphys.2015.00395

- 941 172. Mahmoud AM, Wilkinson FL, McCarthy EM, et al. Endothelial microparticles prevent lipid-induced  
942 endothelial damage via Akt/eNOS signaling and reduced oxidative stress. *FASEB J.* Oct 2017;31(10):4636-  
943 4648. doi:10.1096/fj.201601244RR
- 944 173. Amabile N, Cheng S, Renard JM, et al. Association of circulating endothelial microparticles with  
945 cardiometabolic risk factors in the Framingham Heart Study. *Eur Heart J.* Nov 7 2014;35(42):2972-9.  
946 doi:10.1093/eurheartj/ehu153
- 947 174. Yu Y, Du H, Wei S, et al. Adipocyte-Derived Exosomal MiR-27a Induces Insulin Resistance in  
948 Skeletal Muscle Through Repression of PPARgamma. *Theranostics.* 2018;8(8):2171-2188.  
949 doi:10.7150/thno.22565
- 950 175. Rome S, Forterre A, Mizgier ML, Bouzakri K. Skeletal Muscle-Released Extracellular Vesicles: State  
951 of the Art. *Front Physiol.* 2019;10:929. doi:10.3389/fphys.2019.00929
- 952 176. Hubal MJ, Nadler EP, Ferrante SC, et al. Circulating adipocyte-derived exosomal MicroRNAs  
953 associated with decreased insulin resistance after gastric bypass. *Obesity (Silver Spring).* Jan  
954 2017;25(1):102-110. doi:10.1002/oby.21709
- 955 177. Zhou Y, Tan C. miRNAs in Adipocyte-Derived Extracellular Vesicles: Multiple Roles in Development  
956 of Obesity-Associated Disease. *Front Mol Biosci.* 2020;7:171. doi:10.3389/fmolb.2020.00171
- 957 178. Wu J, Dong T, Chen T, et al. Hepatic exosome-derived miR-130a-3p attenuates glucose intolerance  
958 via suppressing PHLPP2 gene in adipocyte. *Metabolism: clinical and experimental.* Feb 2020;103:154006.  
959 doi:10.1016/j.metabol.2019.154006
- 960 179. Kumar A, Sundaram K, Mu J, et al. High-fat diet-induced upregulation of exosomal  
961 phosphatidylcholine contributes to insulin resistance. *Nat Commun.* Jan 11 2021;12(1):213.  
962 doi:10.1038/s41467-020-20500-w
- 963 180. Mantilla-Escalante DC, Lopez de Las Hazas MC, Crespo MC, et al. Mediterranean diet enriched in  
964 extra-virgin olive oil or nuts modulates circulating exosomal non-coding RNAs. *Eur J Nutr.* May 23  
965 2021;doi:10.1007/s00394-021-02594-0

966

967 **Table Legend:**

968 **Table 1:** Cell surface markers used for the identification of EV subpopulations by flow cytometry.

969 **Table 2:** Clinical trials investigating the impact of acute dietary intakes on EVs during the postprandial  
970 period.

971 **Table 3:** Human intervention studies reporting the effects of (sub)chronic dietary intake on circulating  
972 EVs. C: control diet; I: nutritional intervention.

973 **Legend figures**

974 **Graphical abstract:** Summary of key aims reviewed

975 **Figure 1:** Potential effects of dietary nutrients and metabolites driving the biogenesis and the release of  
976 EVs.

977